DE202010018569U1 - Konservierung zellfreier Nukleinsäuren - Google Patents
Konservierung zellfreier Nukleinsäuren Download PDFInfo
- Publication number
- DE202010018569U1 DE202010018569U1 DE202010018569.6U DE202010018569U DE202010018569U1 DE 202010018569 U1 DE202010018569 U1 DE 202010018569U1 DE 202010018569 U DE202010018569 U DE 202010018569U DE 202010018569 U1 DE202010018569 U1 DE 202010018569U1
- Authority
- DE
- Germany
- Prior art keywords
- collection tube
- blood collection
- blood
- cell
- protective agent
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- 108020004707 nucleic acids Proteins 0.000 title claims abstract description 72
- 102000039446 nucleic acids Human genes 0.000 title claims abstract description 72
- 150000007523 nucleic acids Chemical class 0.000 title claims abstract description 72
- 238000004321 preservation Methods 0.000 title description 6
- 210000004369 blood Anatomy 0.000 claims abstract description 117
- 239000008280 blood Substances 0.000 claims abstract description 117
- 239000003755 preservative agent Substances 0.000 claims abstract description 58
- 230000002335 preservative effect Effects 0.000 claims abstract description 49
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 claims abstract description 40
- -1 vanadyl ribonucleoside complexes Chemical class 0.000 claims abstract description 33
- SOROIESOUPGGFO-UHFFFAOYSA-N diazolidinylurea Chemical compound OCNC(=O)N(CO)C1N(CO)C(=O)N(CO)C1=O SOROIESOUPGGFO-UHFFFAOYSA-N 0.000 claims abstract description 26
- 229960001083 diazolidinylurea Drugs 0.000 claims abstract description 26
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims abstract description 16
- 238000000576 coating method Methods 0.000 claims abstract description 16
- 239000011248 coating agent Substances 0.000 claims abstract description 15
- ZHNUHDYFZUAESO-UHFFFAOYSA-N Formamide Chemical compound NC=O ZHNUHDYFZUAESO-UHFFFAOYSA-N 0.000 claims abstract description 8
- VHJLVAABSRFDPM-QWWZWVQMSA-N dithiothreitol Chemical compound SC[C@@H](O)[C@H](O)CS VHJLVAABSRFDPM-QWWZWVQMSA-N 0.000 claims abstract description 8
- ZCTXEAQXZGPWFG-UHFFFAOYSA-N imidurea Chemical compound O=C1NC(=O)N(CO)C1NC(=O)NCNC(=O)NC1C(=O)NC(=O)N1CO ZCTXEAQXZGPWFG-UHFFFAOYSA-N 0.000 claims abstract description 8
- 229940122426 Nuclease inhibitor Drugs 0.000 claims abstract description 7
- 229920000642 polymer Polymers 0.000 claims abstract description 7
- 150000001768 cations Chemical class 0.000 claims abstract description 5
- 229920005573 silicon-containing polymer Polymers 0.000 claims abstract description 5
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 claims abstract description 4
- XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 claims abstract description 4
- BFNBIHQBYMNNAN-UHFFFAOYSA-N ammonium sulfate Chemical compound N.N.OS(O)(=O)=O BFNBIHQBYMNNAN-UHFFFAOYSA-N 0.000 claims abstract description 4
- 229910052921 ammonium sulfate Inorganic materials 0.000 claims abstract description 4
- 235000011130 ammonium sulphate Nutrition 0.000 claims abstract description 4
- 229910000278 bentonite Inorganic materials 0.000 claims abstract description 4
- 239000000440 bentonite Substances 0.000 claims abstract description 4
- SVPXDRXYRYOSEX-UHFFFAOYSA-N bentoquatam Chemical compound O.O=[Si]=O.O=[Al]O[Al]=O SVPXDRXYRYOSEX-UHFFFAOYSA-N 0.000 claims abstract description 4
- 239000010949 copper Substances 0.000 claims abstract description 4
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 claims abstract description 4
- 235000018417 cysteine Nutrition 0.000 claims abstract description 4
- FFYPMLJYZAEMQB-UHFFFAOYSA-N diethyl pyrocarbonate Chemical compound CCOC(=O)OC(=O)OCC FFYPMLJYZAEMQB-UHFFFAOYSA-N 0.000 claims abstract description 4
- VHJLVAABSRFDPM-ZXZARUISSA-N dithioerythritol Chemical compound SC[C@H](O)[C@H](O)CS VHJLVAABSRFDPM-ZXZARUISSA-N 0.000 claims abstract description 4
- 229960002897 heparin Drugs 0.000 claims abstract description 4
- 229920000669 heparin Polymers 0.000 claims abstract description 4
- DGVVWUTYPXICAM-UHFFFAOYSA-N β‐Mercaptoethanol Chemical compound OCCS DGVVWUTYPXICAM-UHFFFAOYSA-N 0.000 claims abstract description 4
- 108010067770 Endopeptidase K Proteins 0.000 claims abstract description 3
- 239000004793 Polystyrene Substances 0.000 claims abstract description 3
- 229920002313 fluoropolymer Polymers 0.000 claims abstract description 3
- 229920000139 polyethylene terephthalate Polymers 0.000 claims abstract description 3
- 239000005020 polyethylene terephthalate Substances 0.000 claims abstract description 3
- 229920000098 polyolefin Polymers 0.000 claims abstract description 3
- 229920002223 polystyrene Polymers 0.000 claims abstract description 3
- 229920000915 polyvinyl chloride Polymers 0.000 claims abstract description 3
- 239000004800 polyvinyl chloride Substances 0.000 claims abstract description 3
- 230000000087 stabilizing effect Effects 0.000 claims abstract description 3
- 150000003628 tricarboxylic acids Chemical class 0.000 claims abstract description 3
- PBVAJRFEEOIAGW-UHFFFAOYSA-N 3-[bis(2-carboxyethyl)phosphanyl]propanoic acid;hydrochloride Chemical compound Cl.OC(=O)CCP(CCC(O)=O)CCC(O)=O PBVAJRFEEOIAGW-UHFFFAOYSA-N 0.000 claims abstract 2
- 239000003112 inhibitor Substances 0.000 claims description 39
- 108091092259 cell-free RNA Proteins 0.000 claims description 36
- PUZPDOWCWNUUKD-UHFFFAOYSA-M sodium fluoride Chemical compound [F-].[Na+] PUZPDOWCWNUUKD-UHFFFAOYSA-M 0.000 claims description 34
- 239000003223 protective agent Substances 0.000 claims description 29
- 230000002503 metabolic effect Effects 0.000 claims description 27
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 claims description 21
- 235000013024 sodium fluoride Nutrition 0.000 claims description 17
- 239000011775 sodium fluoride Substances 0.000 claims description 17
- MNQZXJOMYWMBOU-VKHMYHEASA-N D-glyceraldehyde Chemical compound OC[C@@H](O)C=O MNQZXJOMYWMBOU-VKHMYHEASA-N 0.000 claims description 16
- YBYRMVIVWMBXKQ-UHFFFAOYSA-N phenylmethanesulfonyl fluoride Chemical compound FS(=O)(=O)CC1=CC=CC=C1 YBYRMVIVWMBXKQ-UHFFFAOYSA-N 0.000 claims description 14
- SEOVTRFCIGRIMH-UHFFFAOYSA-N indole-3-acetic acid Chemical compound C1=CC=C2C(CC(=O)O)=CNC2=C1 SEOVTRFCIGRIMH-UHFFFAOYSA-N 0.000 claims description 12
- GNGACRATGGDKBX-UHFFFAOYSA-N dihydroxyacetone phosphate Chemical compound OCC(=O)COP(O)(O)=O GNGACRATGGDKBX-UHFFFAOYSA-N 0.000 claims description 8
- 229940095758 cantharidin Drugs 0.000 claims description 7
- DHZBEENLJMYSHQ-XCVPVQRUSA-N cantharidin Chemical compound C([C@@H]1O2)C[C@@H]2[C@]2(C)[C@@]1(C)C(=O)OC2=O DHZBEENLJMYSHQ-XCVPVQRUSA-N 0.000 claims description 7
- 229930008397 cantharidin Natural products 0.000 claims description 7
- DHZBEENLJMYSHQ-UHFFFAOYSA-N cantharidine Natural products O1C2CCC1C1(C)C2(C)C(=O)OC1=O DHZBEENLJMYSHQ-UHFFFAOYSA-N 0.000 claims description 7
- 239000000137 peptide hydrolase inhibitor Substances 0.000 claims description 7
- IXBQSRWSVIBXNC-HSKGSTCASA-N Nodularin Chemical compound C([C@H](OC)[C@@H](C)\C=C(/C)\C=C\[C@H]1[C@@H](C(=O)N[C@H](CCC(=O)N(C)C(=C\C)/C(=O)N[C@H]([C@H](C)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N1)C(O)=O)C(O)=O)C)C1=CC=CC=C1 IXBQSRWSVIBXNC-HSKGSTCASA-N 0.000 claims description 6
- IXBQSRWSVIBXNC-UHFFFAOYSA-N Nodularin Natural products N1C(=O)C(CCCN=C(N)N)NC(=O)C(C)C(C(O)=O)NC(=O)C(=CC)N(C)C(=O)CCC(C(O)=O)NC(=O)C(C)C1C=CC(C)=CC(C)C(OC)CC1=CC=CC=C1 IXBQSRWSVIBXNC-UHFFFAOYSA-N 0.000 claims description 6
- RFCWHQNNCOJYTR-IRCAEPKSSA-N Tautomycin Chemical compound O([C@H]([C@H](CC1)C)[C@H](C)CC[C@H](O)[C@H](C)C(=O)C[C@@H](O)[C@@H](OC)[C@H](OC(=O)C[C@@H](O)C=2C(OC(=O)C=2C)=O)C(C)C)[C@@]21CC[C@@H](C)[C@H](CC[C@H](C)C(C)=O)O2 RFCWHQNNCOJYTR-IRCAEPKSSA-N 0.000 claims description 6
- RFCWHQNNCOJYTR-UHFFFAOYSA-N Tautomycin Natural products CC=1C(=O)OC(=O)C=1C(O)CC(=O)OC(C(C)C)C(OC)C(O)CC(=O)C(C)C(O)CCC(C)C(C(CC1)C)OC21CCC(C)C(CCC(C)C(C)=O)O2 RFCWHQNNCOJYTR-UHFFFAOYSA-N 0.000 claims description 6
- 229940122618 Trypsin inhibitor Drugs 0.000 claims description 6
- 101710162629 Trypsin inhibitor Proteins 0.000 claims description 6
- DGEZNRSVGBDHLK-UHFFFAOYSA-N [1,10]phenanthroline Chemical compound C1=CN=C2C3=NC=CC=C3C=CC2=C1 DGEZNRSVGBDHLK-UHFFFAOYSA-N 0.000 claims description 6
- 108010073357 cyanoginosin LR Proteins 0.000 claims description 6
- NYPJDWWKZLNGGM-UHFFFAOYSA-N fenvalerate Chemical compound C=1C=C(Cl)C=CC=1C(C(C)C)C(=O)OC(C#N)C(C=1)=CC=CC=1OC1=CC=CC=C1 NYPJDWWKZLNGGM-UHFFFAOYSA-N 0.000 claims description 6
- 239000003617 indole-3-acetic acid Substances 0.000 claims description 6
- ZYZCGGRZINLQBL-GWRQVWKTSA-N microcystin-LR Chemical compound C([C@H](OC)[C@@H](C)\C=C(/C)\C=C\[C@H]1[C@@H](C(=O)N[C@H](CCC(=O)N(C)C(=C)C(=O)N[C@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@H]([C@H](C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N1)C(O)=O)C(O)=O)C)C1=CC=CC=C1 ZYZCGGRZINLQBL-GWRQVWKTSA-N 0.000 claims description 6
- DIDLWIPCWUSYPF-UHFFFAOYSA-N microcystin-LR Natural products COC(Cc1ccccc1)C(C)C=C(/C)C=CC2NC(=O)C(NC(CCCNC(=N)N)C(=O)O)NC(=O)C(C)C(NC(=O)C(NC(CC(C)C)C(=O)O)NC(=O)C(C)NC(=O)C(=C)N(C)C(=O)CCC(NC(=O)C2C)C(=O)O)C(=O)O DIDLWIPCWUSYPF-UHFFFAOYSA-N 0.000 claims description 6
- 108010065793 nodularin Proteins 0.000 claims description 6
- QNDVLZJODHBUFM-WFXQOWMNSA-N okadaic acid Chemical compound C([C@H](O1)[C@H](C)/C=C/[C@H]2CC[C@@]3(CC[C@H]4O[C@@H](C([C@@H](O)[C@@H]4O3)=C)[C@@H](O)C[C@H](C)[C@@H]3[C@@H](CC[C@@]4(OCCCC4)O3)C)O2)C(C)=C[C@]21O[C@H](C[C@@](C)(O)C(O)=O)CC[C@H]2O QNDVLZJODHBUFM-WFXQOWMNSA-N 0.000 claims description 6
- VEFJHAYOIAAXEU-UHFFFAOYSA-N okadaic acid Natural products CC(CC(O)C1OC2CCC3(CCC(O3)C=CC(C)C4CC(=CC5(OC(CC(C)(O)C(=O)O)CCC5O)O4)C)OC2C(O)C1C)C6OC7(CCCCO7)CCC6C VEFJHAYOIAAXEU-UHFFFAOYSA-N 0.000 claims description 6
- 239000007787 solid Substances 0.000 claims description 6
- 239000002753 trypsin inhibitor Substances 0.000 claims description 6
- 229940124158 Protease/peptidase inhibitor Drugs 0.000 claims description 5
- LXJXRIRHZLFYRP-VKHMYHEASA-L (R)-2-Hydroxy-3-(phosphonooxy)-propanal Natural products O=C[C@H](O)COP([O-])([O-])=O LXJXRIRHZLFYRP-VKHMYHEASA-L 0.000 claims description 4
- MQVDCQIEINPTPF-UHFFFAOYSA-N 2,2-dihydroxyacetic acid;2,3-dihydroxypropanoic acid Chemical compound OC(O)C(O)=O.OCC(O)C(O)=O MQVDCQIEINPTPF-UHFFFAOYSA-N 0.000 claims description 4
- BXVSAYBZSGIURM-UHFFFAOYSA-N 2-phenoxy-4h-1,3,2$l^{5}-benzodioxaphosphinine 2-oxide Chemical compound O1CC2=CC=CC=C2OP1(=O)OC1=CC=CC=C1 BXVSAYBZSGIURM-UHFFFAOYSA-N 0.000 claims description 4
- GXIURPTVHJPJLF-UWTATZPHSA-N 2-phosphoglycerate Natural products OC[C@H](C(O)=O)OP(O)(O)=O GXIURPTVHJPJLF-UWTATZPHSA-N 0.000 claims description 4
- GXIURPTVHJPJLF-UHFFFAOYSA-N 2-phosphoglyceric acid Chemical compound OCC(C(O)=O)OP(O)(O)=O GXIURPTVHJPJLF-UHFFFAOYSA-N 0.000 claims description 4
- OSJPPGNTCRNQQC-UWTATZPHSA-N 3-phospho-D-glyceric acid Chemical compound OC(=O)[C@H](O)COP(O)(O)=O OSJPPGNTCRNQQC-UWTATZPHSA-N 0.000 claims description 4
- LJQLQCAXBUHEAZ-UWTATZPHSA-N 3-phospho-D-glyceroyl dihydrogen phosphate Chemical compound OP(=O)(O)OC[C@@H](O)C(=O)OP(O)(O)=O LJQLQCAXBUHEAZ-UWTATZPHSA-N 0.000 claims description 4
- LXJXRIRHZLFYRP-VKHMYHEASA-N D-glyceraldehyde 3-phosphate Chemical compound O=C[C@H](O)COP(O)(O)=O LXJXRIRHZLFYRP-VKHMYHEASA-N 0.000 claims description 4
- LCTONWCANYUPML-UHFFFAOYSA-M Pyruvate Chemical compound CC(=O)C([O-])=O LCTONWCANYUPML-UHFFFAOYSA-M 0.000 claims description 4
- 229930029653 phosphoenolpyruvate Natural products 0.000 claims description 4
- DTBNBXWJWCWCIK-UHFFFAOYSA-N phosphoenolpyruvic acid Chemical compound OC(=O)C(=C)OP(O)(O)=O DTBNBXWJWCWCIK-UHFFFAOYSA-N 0.000 claims description 4
- IHIXIJGXTJIKRB-UHFFFAOYSA-N trisodium vanadate Chemical compound [Na+].[Na+].[Na+].[O-][V]([O-])([O-])=O IHIXIJGXTJIKRB-UHFFFAOYSA-N 0.000 claims description 4
- GXEKYRXVRROBEV-FBXFSONDSA-N (1r,2s,3r,4s)-7-oxabicyclo[2.2.1]heptane-2,3-dicarboxylic acid Chemical compound C1C[C@@H]2[C@@H](C(O)=O)[C@@H](C(=O)O)[C@H]1O2 GXEKYRXVRROBEV-FBXFSONDSA-N 0.000 claims description 3
- JNTMAZFVYNDPLB-PEDHHIEDSA-N (2S,3S)-2-[[[(2S)-1-[(2S,3S)-2-amino-3-methyl-1-oxopentyl]-2-pyrrolidinyl]-oxomethyl]amino]-3-methylpentanoic acid Chemical compound CC[C@H](C)[C@H](N)C(=O)N1CCC[C@H]1C(=O)N[C@@H]([C@@H](C)CC)C(O)=O JNTMAZFVYNDPLB-PEDHHIEDSA-N 0.000 claims description 3
- MRXDGVXSWIXTQL-HYHFHBMOSA-N (2s)-2-[[(1s)-1-(2-amino-1,4,5,6-tetrahydropyrimidin-6-yl)-2-[[(2s)-4-methyl-1-oxo-1-[[(2s)-1-oxo-3-phenylpropan-2-yl]amino]pentan-2-yl]amino]-2-oxoethyl]carbamoylamino]-3-phenylpropanoic acid Chemical compound C([C@H](NC(=O)N[C@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=1C=CC=CC=1)C=O)C1NC(N)=NCC1)C(O)=O)C1=CC=CC=C1 MRXDGVXSWIXTQL-HYHFHBMOSA-N 0.000 claims description 3
- IJWCGVPEDDQUDE-YGJAXBLXSA-N (2s)-2-[[(1s)-2-[[(2s)-5-amino-1,5-dioxo-1-[[(2s)-1-oxopropan-2-yl]amino]pentan-2-yl]amino]-1-[(6s)-2-amino-1,4,5,6-tetrahydropyrimidin-6-yl]-2-oxoethyl]carbamoylamino]-4-methylpentanoic acid Chemical compound O=C[C@H](C)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)N[C@@H](CC(C)C)C(O)=O)[C@@H]1CCN=C(N)N1 IJWCGVPEDDQUDE-YGJAXBLXSA-N 0.000 claims description 3
- PMHUSCHKTSTQEP-UHFFFAOYSA-N (4-carbamimidoylphenyl)methanesulfonyl fluoride Chemical compound NC(=N)C1=CC=C(CS(F)(=O)=O)C=C1 PMHUSCHKTSTQEP-UHFFFAOYSA-N 0.000 claims description 3
- QCVGEOXPDFCNHA-UHFFFAOYSA-N 5,5-dimethyl-2,4-dioxo-1,3-oxazolidine-3-carboxamide Chemical compound CC1(C)OC(=O)N(C(N)=O)C1=O QCVGEOXPDFCNHA-UHFFFAOYSA-N 0.000 claims description 3
- 102100033312 Alpha-2-macroglobulin Human genes 0.000 claims description 3
- 108010087765 Antipain Proteins 0.000 claims description 3
- 108010039627 Aprotinin Proteins 0.000 claims description 3
- VGGGPCQERPFHOB-MCIONIFRSA-N Bestatin Chemical compound CC(C)C[C@H](C(O)=O)NC(=O)[C@@H](O)[C@H](N)CC1=CC=CC=C1 VGGGPCQERPFHOB-MCIONIFRSA-N 0.000 claims description 3
- VGGGPCQERPFHOB-UHFFFAOYSA-N Bestatin Natural products CC(C)CC(C(O)=O)NC(=O)C(O)C(N)CC1=CC=CC=C1 VGGGPCQERPFHOB-UHFFFAOYSA-N 0.000 claims description 3
- 244000045232 Canavalia ensiformis Species 0.000 claims description 3
- OLVPQBGMUGIKIW-UHFFFAOYSA-N Chymostatin Natural products C=1C=CC=CC=1CC(C=O)NC(=O)C(C(C)CC)NC(=O)C(C1NC(N)=NCC1)NC(=O)NC(C(O)=O)CC1=CC=CC=C1 OLVPQBGMUGIKIW-UHFFFAOYSA-N 0.000 claims description 3
- 229930105110 Cyclosporin A Natural products 0.000 claims description 3
- PMATZTZNYRCHOR-CGLBZJNRSA-N Cyclosporin A Chemical compound CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O PMATZTZNYRCHOR-CGLBZJNRSA-N 0.000 claims description 3
- 108010036949 Cyclosporine Proteins 0.000 claims description 3
- 239000005946 Cypermethrin Substances 0.000 claims description 3
- 239000005892 Deltamethrin Substances 0.000 claims description 3
- 102000002322 Egg Proteins Human genes 0.000 claims description 3
- 108010000912 Egg Proteins Proteins 0.000 claims description 3
- IJWCGVPEDDQUDE-UHFFFAOYSA-N Elastatinal Natural products O=CC(C)NC(=O)C(CCC(N)=O)NC(=O)C(NC(=O)NC(CC(C)C)C(O)=O)C1CCN=C(N)N1 IJWCGVPEDDQUDE-UHFFFAOYSA-N 0.000 claims description 3
- 244000068988 Glycine max Species 0.000 claims description 3
- 235000010469 Glycine max Nutrition 0.000 claims description 3
- 102000000521 Immunophilins Human genes 0.000 claims description 3
- 108010016648 Immunophilins Proteins 0.000 claims description 3
- GDBQQVLCIARPGH-UHFFFAOYSA-N Leupeptin Natural products CC(C)CC(NC(C)=O)C(=O)NC(CC(C)C)C(=O)NC(C=O)CCCN=C(N)N GDBQQVLCIARPGH-UHFFFAOYSA-N 0.000 claims description 3
- MQUQNUAYKLCRME-INIZCTEOSA-N N-tosyl-L-phenylalanyl chloromethyl ketone Chemical compound C1=CC(C)=CC=C1S(=O)(=O)N[C@H](C(=O)CCl)CC1=CC=CC=C1 MQUQNUAYKLCRME-INIZCTEOSA-N 0.000 claims description 3
- 235000010617 Phaseolus lunatus Nutrition 0.000 claims description 3
- YNPNZTXNASCQKK-UHFFFAOYSA-N Phenanthrene Natural products C1=CC=C2C3=CC=CC=C3C=CC2=C1 YNPNZTXNASCQKK-UHFFFAOYSA-N 0.000 claims description 3
- 229940122907 Phosphatase inhibitor Drugs 0.000 claims description 3
- 108010015078 Pregnancy-Associated alpha 2-Macroglobulins Proteins 0.000 claims description 3
- 108090000506 Protein phosphatase inhibitor 1 Proteins 0.000 claims description 3
- 102000004097 Protein phosphatase inhibitor 1 Human genes 0.000 claims description 3
- QJJXYPPXXYFBGM-LFZNUXCKSA-N Tacrolimus Chemical compound C1C[C@@H](O)[C@H](OC)C[C@@H]1\C=C(/C)[C@@H]1[C@H](C)[C@@H](O)CC(=O)[C@H](CC=C)/C=C(C)/C[C@H](C)C[C@H](OC)[C@H]([C@H](C[C@H]2C)OC)O[C@@]2(O)C(=O)C(=O)N2CCCC[C@H]2C(=O)O1 QJJXYPPXXYFBGM-LFZNUXCKSA-N 0.000 claims description 3
- NHXZRXLFOBFMDM-AVGNSLFASA-N Val-Pro-Leu Chemical compound CC(C)C[C@@H](C(O)=O)NC(=O)[C@@H]1CCCN1C(=O)[C@@H](N)C(C)C NHXZRXLFOBFMDM-AVGNSLFASA-N 0.000 claims description 3
- ZMQRJWIYMXZORG-GZIFKOAOSA-N [(1e,3r,4r,6r,7z,9z,11e)-3,6,13-trihydroxy-3-methyl-1-[(2s)-6-oxo-2,3-dihydropyran-2-yl]trideca-1,7,9,11-tetraen-4-yl] dihydrogen phosphate Chemical compound OC/C=C/C=C\C=C/[C@H](O)C[C@@H](OP(O)(O)=O)[C@@](O)(C)\C=C\[C@@H]1CC=CC(=O)O1 ZMQRJWIYMXZORG-GZIFKOAOSA-N 0.000 claims description 3
- FKAWLXNLHHIHLA-YCBIHMBMSA-N [(2r,3r,5r,7r,8s,9s)-2-[(1s,3s,4s,5r,6r,7e,9e,11e,13z)-14-cyano-3,5-dihydroxy-1-methoxy-4,6,8,9,13-pentamethyltetradeca-7,9,11,13-tetraenyl]-9-[(e)-3-[2-[(2s)-4-[[(2s,3s,4s)-4-(dimethylamino)-2,3-dihydroxy-5-methoxypentanoyl]amino]butan-2-yl]-1,3-oxazol-4 Chemical compound O1C([C@@H](C)CCNC(=O)[C@@H](O)[C@@H](O)[C@H](COC)N(C)C)=NC(\C=C\C[C@H]2[C@H]([C@H](O)C[C@]3(O2)C([C@@H](OP(O)(O)=O)[C@@H]([C@H](C[C@H](O)[C@H](C)[C@H](O)[C@H](C)\C=C(/C)\C(\C)=C\C=C\C(\C)=C/C#N)OC)O3)(C)C)C)=C1 FKAWLXNLHHIHLA-YCBIHMBMSA-N 0.000 claims description 3
- QFAADIRHLBXJJS-ZAZJUGBXSA-N amastatin Chemical compound CC(C)C[C@@H](N)[C@H](O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@H](C(O)=O)CC(O)=O QFAADIRHLBXJJS-ZAZJUGBXSA-N 0.000 claims description 3
- 108010052590 amastatin Proteins 0.000 claims description 3
- SDNYTAYICBFYFH-TUFLPTIASA-N antipain Chemical compound NC(N)=NCCC[C@@H](C=O)NC(=O)[C@H](C(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)N[C@H](C(O)=O)CC1=CC=CC=C1 SDNYTAYICBFYFH-TUFLPTIASA-N 0.000 claims description 3
- 229960004405 aprotinin Drugs 0.000 claims description 3
- 108010086192 chymostatin Proteins 0.000 claims description 3
- 229960001265 ciclosporin Drugs 0.000 claims description 3
- 229960005424 cypermethrin Drugs 0.000 claims description 3
- KAATUXNTWXVJKI-UHFFFAOYSA-N cypermethrin Chemical compound CC1(C)C(C=C(Cl)Cl)C1C(=O)OC(C#N)C1=CC=CC(OC=2C=CC=CC=2)=C1 KAATUXNTWXVJKI-UHFFFAOYSA-N 0.000 claims description 3
- 108050004038 cystatin Proteins 0.000 claims description 3
- 229960002483 decamethrin Drugs 0.000 claims description 3
- OWZREIFADZCYQD-NSHGMRRFSA-N deltamethrin Chemical compound CC1(C)[C@@H](C=C(Br)Br)[C@H]1C(=O)O[C@H](C#N)C1=CC=CC(OC=2C=CC=CC=2)=C1 OWZREIFADZCYQD-NSHGMRRFSA-N 0.000 claims description 3
- HCJOLYFWJWJPTJ-UHFFFAOYSA-N dephostatin Chemical compound O=NN(C)C1=CC(O)=CC=C1O HCJOLYFWJWJPTJ-UHFFFAOYSA-N 0.000 claims description 3
- 108010054812 diprotin A Proteins 0.000 claims description 3
- 108010054813 diprotin B Proteins 0.000 claims description 3
- 235000014103 egg white Nutrition 0.000 claims description 3
- 210000000969 egg white Anatomy 0.000 claims description 3
- 108010039262 elastatinal Proteins 0.000 claims description 3
- 229950010404 fostriecin Drugs 0.000 claims description 3
- ZPNFWUPYTFPOJU-LPYSRVMUSA-N iniprol Chemical compound C([C@H]1C(=O)NCC(=O)NCC(=O)N[C@H]2CSSC[C@H]3C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@H](C(N[C@H](C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=4C=CC(O)=CC=4)C(=O)N[C@@H](CC=4C=CC=CC=4)C(=O)N[C@@H](CC=4C=CC(O)=CC=4)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CC=4C=CC=CC=4)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC2=O)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](CC=2C=CC=CC=2)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H]2N(CCC2)C(=O)[C@@H](N)CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N2[C@@H](CCC2)C(=O)N2[C@@H](CCC2)C(=O)N[C@@H](CC=2C=CC(O)=CC=2)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N2[C@@H](CCC2)C(=O)N3)C(=O)NCC(=O)NCC(=O)N[C@@H](C)C(O)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@H](C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@H](C(=O)N1)C(C)C)[C@@H](C)O)[C@@H](C)CC)=O)[C@@H](C)CC)C1=CC=C(O)C=C1 ZPNFWUPYTFPOJU-LPYSRVMUSA-N 0.000 claims description 3
- GDBQQVLCIARPGH-ULQDDVLXSA-N leupeptin Chemical compound CC(C)C[C@H](NC(C)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@H](C=O)CCCN=C(N)N GDBQQVLCIARPGH-ULQDDVLXSA-N 0.000 claims description 3
- 108010052968 leupeptin Proteins 0.000 claims description 3
- YFCUZWYIPBUQBD-ZOWNYOTGSA-N n-[(3s)-7-amino-1-chloro-2-oxoheptan-3-yl]-4-methylbenzenesulfonamide;hydron;chloride Chemical compound Cl.CC1=CC=C(S(=O)(=O)N[C@@H](CCCCN)C(=O)CCl)C=C1 YFCUZWYIPBUQBD-ZOWNYOTGSA-N 0.000 claims description 3
- 108010000416 ovomacroglobulin Proteins 0.000 claims description 3
- 229950000964 pepstatin Drugs 0.000 claims description 3
- 108010091212 pepstatin Proteins 0.000 claims description 3
- FAXGPCHRFPCXOO-LXTPJMTPSA-N pepstatin A Chemical compound OC(=O)C[C@H](O)[C@H](CC(C)C)NC(=O)[C@H](C)NC(=O)C[C@H](O)[C@H](CC(C)C)NC(=O)[C@H](C(C)C)NC(=O)[C@H](C(C)C)NC(=O)CC(C)C FAXGPCHRFPCXOO-LXTPJMTPSA-N 0.000 claims description 3
- 229950009811 ubenimex Drugs 0.000 claims description 3
- 229930040373 Paraformaldehyde Natural products 0.000 claims description 2
- 229920002866 paraformaldehyde Polymers 0.000 claims description 2
- 150000004756 silanes Chemical class 0.000 claims description 2
- 102000015833 Cystatin Human genes 0.000 claims 1
- 210000002381 plasma Anatomy 0.000 description 38
- 101710163270 Nuclease Proteins 0.000 description 23
- 238000000034 method Methods 0.000 description 19
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 18
- 210000000601 blood cell Anatomy 0.000 description 18
- 239000002532 enzyme inhibitor Substances 0.000 description 14
- 238000002955 isolation Methods 0.000 description 12
- 239000000203 mixture Substances 0.000 description 12
- 238000003752 polymerase chain reaction Methods 0.000 description 12
- 108090000623 proteins and genes Proteins 0.000 description 12
- 102000004169 proteins and genes Human genes 0.000 description 10
- 230000006037 cell lysis Effects 0.000 description 9
- 230000000694 effects Effects 0.000 description 9
- 238000012360 testing method Methods 0.000 description 9
- 210000004027 cell Anatomy 0.000 description 8
- 108091092328 cellular RNA Proteins 0.000 description 8
- 239000000834 fixative Substances 0.000 description 8
- 239000007788 liquid Substances 0.000 description 8
- 108020004999 messenger RNA Proteins 0.000 description 8
- 230000015556 catabolic process Effects 0.000 description 7
- 238000006731 degradation reaction Methods 0.000 description 7
- 201000010099 disease Diseases 0.000 description 7
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 7
- 238000005259 measurement Methods 0.000 description 7
- 108020004463 18S ribosomal RNA Proteins 0.000 description 6
- 206010028980 Neoplasm Diseases 0.000 description 6
- 108091005804 Peptidases Proteins 0.000 description 6
- 239000004365 Protease Substances 0.000 description 6
- 230000019522 cellular metabolic process Effects 0.000 description 6
- 150000001875 compounds Chemical class 0.000 description 6
- RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Natural products C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 description 6
- 235000018102 proteins Nutrition 0.000 description 6
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 5
- 102000006382 Ribonucleases Human genes 0.000 description 5
- 108010083644 Ribonucleases Proteins 0.000 description 5
- 239000013543 active substance Substances 0.000 description 5
- 229940125532 enzyme inhibitor Drugs 0.000 description 5
- 239000008103 glucose Substances 0.000 description 5
- 230000002829 reductive effect Effects 0.000 description 5
- 239000000243 solution Substances 0.000 description 5
- 230000006819 RNA synthesis Effects 0.000 description 4
- 102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 description 4
- 230000001640 apoptogenic effect Effects 0.000 description 4
- 201000011510 cancer Diseases 0.000 description 4
- 239000004615 ingredient Substances 0.000 description 4
- 230000002401 inhibitory effect Effects 0.000 description 4
- 230000001404 mediated effect Effects 0.000 description 4
- 235000019419 proteases Nutrition 0.000 description 4
- 238000003757 reverse transcription PCR Methods 0.000 description 4
- 238000012216 screening Methods 0.000 description 4
- ATHGHQPFGPMSJY-UHFFFAOYSA-N spermidine Chemical compound NCCCCNCCCN ATHGHQPFGPMSJY-UHFFFAOYSA-N 0.000 description 4
- PFNFFQXMRSDOHW-UHFFFAOYSA-N spermine Chemical compound NCCCNCCCCNCCCN PFNFFQXMRSDOHW-UHFFFAOYSA-N 0.000 description 4
- 102000004160 Phosphoric Monoester Hydrolases Human genes 0.000 description 3
- 108090000608 Phosphoric Monoester Hydrolases Proteins 0.000 description 3
- 238000004458 analytical method Methods 0.000 description 3
- 238000010241 blood sampling Methods 0.000 description 3
- 210000000170 cell membrane Anatomy 0.000 description 3
- 230000001413 cellular effect Effects 0.000 description 3
- 239000003795 chemical substances by application Substances 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 238000002156 mixing Methods 0.000 description 3
- 229920000768 polyamine Polymers 0.000 description 3
- 230000008569 process Effects 0.000 description 3
- 125000000143 2-carboxyethyl group Chemical group [H]OC(=O)C([H])([H])C([H])([H])* 0.000 description 2
- LVDKZNITIUWNER-UHFFFAOYSA-N Bronopol Chemical compound OCC(Br)(CO)[N+]([O-])=O LVDKZNITIUWNER-UHFFFAOYSA-N 0.000 description 2
- 102000016911 Deoxyribonucleases Human genes 0.000 description 2
- 108010053770 Deoxyribonucleases Proteins 0.000 description 2
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- 102000035195 Peptidases Human genes 0.000 description 2
- XYFCBTPGUUZFHI-UHFFFAOYSA-N Phosphine Chemical compound P XYFCBTPGUUZFHI-UHFFFAOYSA-N 0.000 description 2
- 206010034962 Photopsia Diseases 0.000 description 2
- 238000011529 RT qPCR Methods 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 2
- 239000007983 Tris buffer Substances 0.000 description 2
- 241000700605 Viruses Species 0.000 description 2
- ORILYTVJVMAKLC-UHFFFAOYSA-N adamantane Chemical group C1C(C2)CC3CC1CC2C3 ORILYTVJVMAKLC-UHFFFAOYSA-N 0.000 description 2
- 229910001573 adamantine Inorganic materials 0.000 description 2
- GIXWDMTZECRIJT-UHFFFAOYSA-N aurintricarboxylic acid Chemical compound C1=CC(=O)C(C(=O)O)=CC1=C(C=1C=C(C(O)=CC=1)C(O)=O)C1=CC=C(O)C(C(O)=O)=C1 GIXWDMTZECRIJT-UHFFFAOYSA-N 0.000 description 2
- 239000010836 blood and blood product Substances 0.000 description 2
- 229940125691 blood product Drugs 0.000 description 2
- 239000007975 buffered saline Substances 0.000 description 2
- VHRGRCVQAFMJIZ-UHFFFAOYSA-N cadaverine Chemical compound NCCCCCN VHRGRCVQAFMJIZ-UHFFFAOYSA-N 0.000 description 2
- 238000005119 centrifugation Methods 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 239000000356 contaminant Substances 0.000 description 2
- 229920001577 copolymer Polymers 0.000 description 2
- 238000010790 dilution Methods 0.000 description 2
- 239000012895 dilution Substances 0.000 description 2
- 229940042399 direct acting antivirals protease inhibitors Drugs 0.000 description 2
- WSDISUOETYTPRL-UHFFFAOYSA-N dmdm hydantoin Chemical compound CC1(C)N(CO)C(=O)N(CO)C1=O WSDISUOETYTPRL-UHFFFAOYSA-N 0.000 description 2
- 238000007710 freezing Methods 0.000 description 2
- 230000008014 freezing Effects 0.000 description 2
- 239000011521 glass Substances 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 238000011534 incubation Methods 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- 238000009413 insulation Methods 0.000 description 2
- 239000003550 marker Substances 0.000 description 2
- 230000008774 maternal effect Effects 0.000 description 2
- 239000012528 membrane Substances 0.000 description 2
- 230000004060 metabolic process Effects 0.000 description 2
- 108700019599 monomethylolglycine Proteins 0.000 description 2
- 150000002917 oxazolidines Chemical class 0.000 description 2
- QUBQYFYWUJJAAK-UHFFFAOYSA-N oxymethurea Chemical compound OCNC(=O)NCO QUBQYFYWUJJAAK-UHFFFAOYSA-N 0.000 description 2
- 229950005308 oxymethurea Drugs 0.000 description 2
- 150000002989 phenols Chemical class 0.000 description 2
- 229910000065 phosphene Inorganic materials 0.000 description 2
- 238000007858 polymerase cycling assembly Methods 0.000 description 2
- 238000012545 processing Methods 0.000 description 2
- KIDHWZJUCRJVML-UHFFFAOYSA-N putrescine Chemical compound NCCCCN KIDHWZJUCRJVML-UHFFFAOYSA-N 0.000 description 2
- 238000003753 real-time PCR Methods 0.000 description 2
- 229940101011 sodium hydroxymethylglycinate Drugs 0.000 description 2
- CITBNDNUEPMTFC-UHFFFAOYSA-M sodium;2-(hydroxymethylamino)acetate Chemical compound [Na+].OCNCC([O-])=O CITBNDNUEPMTFC-UHFFFAOYSA-M 0.000 description 2
- 229940063673 spermidine Drugs 0.000 description 2
- 229940063675 spermine Drugs 0.000 description 2
- 230000002195 synergetic effect Effects 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- BUHVIAUBTBOHAG-FOYDDCNASA-N (2r,3r,4s,5r)-2-[6-[[2-(3,5-dimethoxyphenyl)-2-(2-methylphenyl)ethyl]amino]purin-9-yl]-5-(hydroxymethyl)oxolane-3,4-diol Chemical compound COC1=CC(OC)=CC(C(CNC=2C=3N=CN(C=3N=CN=2)[C@H]2[C@@H]([C@H](O)[C@@H](CO)O2)O)C=2C(=CC=CC=2)C)=C1 BUHVIAUBTBOHAG-FOYDDCNASA-N 0.000 description 1
- BFHKYHMIVDBCPC-UHFFFAOYSA-N 1,3,5,7-tetrahydro-[1,3]oxazolo[3,4-c][1,3]oxazol-7a-ylmethanol Chemical compound C1OCN2COCC21CO BFHKYHMIVDBCPC-UHFFFAOYSA-N 0.000 description 1
- 108700028369 Alleles Proteins 0.000 description 1
- JPVYNHNXODAKFH-UHFFFAOYSA-N Cu2+ Chemical compound [Cu+2] JPVYNHNXODAKFH-UHFFFAOYSA-N 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 235000014820 Galium aparine Nutrition 0.000 description 1
- 240000005702 Galium aparine Species 0.000 description 1
- ZRALSGWEFCBTJO-UHFFFAOYSA-N Guanidine Chemical class NC(N)=N ZRALSGWEFCBTJO-UHFFFAOYSA-N 0.000 description 1
- 102100021519 Hemoglobin subunit beta Human genes 0.000 description 1
- 108091005904 Hemoglobin subunit beta Proteins 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 108060004795 Methyltransferase Proteins 0.000 description 1
- 108091005461 Nucleic proteins Proteins 0.000 description 1
- 239000004698 Polyethylene Substances 0.000 description 1
- 239000004743 Polypropylene Substances 0.000 description 1
- 239000005700 Putrescine Substances 0.000 description 1
- 238000002123 RNA extraction Methods 0.000 description 1
- LCEISKAANHGSNY-UHFFFAOYSA-N [O].ON Chemical compound [O].ON LCEISKAANHGSNY-UHFFFAOYSA-N 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 239000002318 adhesion promoter Substances 0.000 description 1
- 238000000246 agarose gel electrophoresis Methods 0.000 description 1
- 230000003321 amplification Effects 0.000 description 1
- 229940035674 anesthetics Drugs 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 239000000739 antihistaminic agent Substances 0.000 description 1
- 229940125715 antihistaminic agent Drugs 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 230000006907 apoptotic process Effects 0.000 description 1
- 206010003246 arthritis Diseases 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- 239000003613 bile acid Substances 0.000 description 1
- 229920001400 block copolymer Polymers 0.000 description 1
- 238000009534 blood test Methods 0.000 description 1
- 239000005388 borosilicate glass Substances 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 238000005251 capillar electrophoresis Methods 0.000 description 1
- 230000030833 cell death Effects 0.000 description 1
- 230000004663 cell proliferation Effects 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 230000002301 combined effect Effects 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 238000011109 contamination Methods 0.000 description 1
- 238000004132 cross linking Methods 0.000 description 1
- 230000007850 degeneration Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 230000003292 diminished effect Effects 0.000 description 1
- 230000009977 dual effect Effects 0.000 description 1
- DEFVIWRASFVYLL-UHFFFAOYSA-N ethylene glycol bis(2-aminoethyl)tetraacetic acid Chemical compound OC(=O)CN(CC(O)=O)CCOCCOCCN(CC(O)=O)CC(O)=O DEFVIWRASFVYLL-UHFFFAOYSA-N 0.000 description 1
- 230000001605 fetal effect Effects 0.000 description 1
- 239000012467 final product Substances 0.000 description 1
- 238000001917 fluorescence detection Methods 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 238000001502 gel electrophoresis Methods 0.000 description 1
- 239000003193 general anesthetic agent Substances 0.000 description 1
- 230000004153 glucose metabolism Effects 0.000 description 1
- MNQZXJOMYWMBOU-UHFFFAOYSA-N glyceraldehyde Chemical class OCC(O)C=O MNQZXJOMYWMBOU-UHFFFAOYSA-N 0.000 description 1
- 229920000578 graft copolymer Polymers 0.000 description 1
- 230000005802 health problem Effects 0.000 description 1
- 238000009396 hybridization Methods 0.000 description 1
- 229920001477 hydrophilic polymer Polymers 0.000 description 1
- 230000002209 hydrophobic effect Effects 0.000 description 1
- 229920001600 hydrophobic polymer Polymers 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 238000007403 mPCR Methods 0.000 description 1
- 238000004949 mass spectrometry Methods 0.000 description 1
- 230000011987 methylation Effects 0.000 description 1
- 238000007069 methylation reaction Methods 0.000 description 1
- 125000005699 methyleneoxy group Chemical group [H]C([H])([*:1])O[*:2] 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 238000003199 nucleic acid amplification method Methods 0.000 description 1
- 238000007826 nucleic acid assay Methods 0.000 description 1
- 238000004806 packaging method and process Methods 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- 229920000573 polyethylene Polymers 0.000 description 1
- 239000002861 polymer material Substances 0.000 description 1
- 229920001155 polypropylene Polymers 0.000 description 1
- 229920001343 polytetrafluoroethylene Polymers 0.000 description 1
- 239000004810 polytetrafluoroethylene Substances 0.000 description 1
- 230000035935 pregnancy Effects 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 239000011814 protection agent Substances 0.000 description 1
- 239000011253 protective coating Substances 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 239000003161 ribonuclease inhibitor Substances 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 239000007790 solid phase Substances 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 230000006641 stabilisation Effects 0.000 description 1
- 238000011105 stabilization Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 239000012780 transparent material Substances 0.000 description 1
- 210000004881 tumor cell Anatomy 0.000 description 1
- 238000000870 ultraviolet spectroscopy Methods 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6806—Preparing nucleic acids for analysis, e.g. for polymerase chain reaction [PCR] assay
-
- C—CHEMISTRY; METALLURGY
- C09—DYES; PAINTS; POLISHES; NATURAL RESINS; ADHESIVES; COMPOSITIONS NOT OTHERWISE PROVIDED FOR; APPLICATIONS OF MATERIALS NOT OTHERWISE PROVIDED FOR
- C09K—MATERIALS FOR MISCELLANEOUS APPLICATIONS, NOT PROVIDED FOR ELSEWHERE
- C09K15/00—Anti-oxidant compositions; Compositions inhibiting chemical change
- C09K15/04—Anti-oxidant compositions; Compositions inhibiting chemical change containing organic compounds
- C09K15/20—Anti-oxidant compositions; Compositions inhibiting chemical change containing organic compounds containing nitrogen and oxygen
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
- C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2527/00—Reactions demanding special reaction conditions
- C12Q2527/125—Specific component of sample, medium or buffer
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2527/00—Reactions demanding special reaction conditions
- C12Q2527/127—Reactions demanding special reaction conditions the enzyme inhibitor or activator used
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Analytical Chemistry (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Health & Medical Sciences (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- Biophysics (AREA)
- Physics & Mathematics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Immunology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Materials Engineering (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Investigating Or Analysing Biological Materials (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US15347209P | 2009-02-18 | 2009-02-18 | |
| US61/153,472 | 2009-02-18 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DE202010018569U1 true DE202010018569U1 (de) | 2017-09-26 |
Family
ID=42112198
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DE202010018569.6U Expired - Lifetime DE202010018569U1 (de) | 2009-02-18 | 2010-02-11 | Konservierung zellfreier Nukleinsäuren |
Country Status (7)
| Country | Link |
|---|---|
| US (10) | US8304187B2 (https=) |
| EP (3) | EP3778919A1 (https=) |
| DE (1) | DE202010018569U1 (https=) |
| DK (2) | DK3290530T3 (https=) |
| ES (1) | ES2649572T3 (https=) |
| NO (1) | NO2398912T3 (https=) |
| WO (1) | WO2010096323A1 (https=) |
Families Citing this family (122)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2445204C (en) | 2002-10-16 | 2014-08-12 | Streck Laboratories, Inc. | Method and device for collecting and preserving cells for analysis |
| US8532930B2 (en) | 2005-11-26 | 2013-09-10 | Natera, Inc. | Method for determining the number of copies of a chromosome in the genome of a target individual using genetic data from genetically related individuals |
| US11111544B2 (en) | 2005-07-29 | 2021-09-07 | Natera, Inc. | System and method for cleaning noisy genetic data and determining chromosome copy number |
| US10083273B2 (en) | 2005-07-29 | 2018-09-25 | Natera, Inc. | System and method for cleaning noisy genetic data and determining chromosome copy number |
| US10081839B2 (en) | 2005-07-29 | 2018-09-25 | Natera, Inc | System and method for cleaning noisy genetic data and determining chromosome copy number |
| US9424392B2 (en) | 2005-11-26 | 2016-08-23 | Natera, Inc. | System and method for cleaning noisy genetic data from target individuals using genetic data from genetically related individuals |
| US11111543B2 (en) | 2005-07-29 | 2021-09-07 | Natera, Inc. | System and method for cleaning noisy genetic data and determining chromosome copy number |
| EP2321642B1 (en) | 2008-08-04 | 2017-01-11 | Natera, Inc. | Methods for allele calling and ploidy calling |
| WO2010078194A1 (en) * | 2008-12-30 | 2010-07-08 | Streck, Inc. | Method for screening blood using a preservative that may be in a substantially solid state form |
| US11634747B2 (en) * | 2009-01-21 | 2023-04-25 | Streck Llc | Preservation of fetal nucleic acids in maternal plasma |
| NO2398912T3 (https=) | 2009-02-18 | 2018-02-10 | ||
| WO2011041485A1 (en) | 2009-09-30 | 2011-04-07 | Gene Security Network, Inc. | Methods for non-invasive prenatal ploidy calling |
| US20110111410A1 (en) * | 2009-11-09 | 2011-05-12 | Streck, Inc. | Stabilization of rna in intact cells within a blood sample |
| WO2011113043A2 (en) * | 2010-03-12 | 2011-09-15 | University Of South Florida | Sample storage for molecular and immunological detection |
| US11322224B2 (en) | 2010-05-18 | 2022-05-03 | Natera, Inc. | Methods for non-invasive prenatal ploidy calling |
| US12221653B2 (en) | 2010-05-18 | 2025-02-11 | Natera, Inc. | Methods for simultaneous amplification of target loci |
| US12545960B2 (en) | 2010-05-18 | 2026-02-10 | Natera, Inc. | Methods for simultaneous amplification of target loci |
| US11332785B2 (en) | 2010-05-18 | 2022-05-17 | Natera, Inc. | Methods for non-invasive prenatal ploidy calling |
| US9677118B2 (en) | 2014-04-21 | 2017-06-13 | Natera, Inc. | Methods for simultaneous amplification of target loci |
| US11408031B2 (en) | 2010-05-18 | 2022-08-09 | Natera, Inc. | Methods for non-invasive prenatal paternity testing |
| US12152275B2 (en) | 2010-05-18 | 2024-11-26 | Natera, Inc. | Methods for non-invasive prenatal ploidy calling |
| US11339429B2 (en) | 2010-05-18 | 2022-05-24 | Natera, Inc. | Methods for non-invasive prenatal ploidy calling |
| US11939634B2 (en) | 2010-05-18 | 2024-03-26 | Natera, Inc. | Methods for simultaneous amplification of target loci |
| US20190010543A1 (en) | 2010-05-18 | 2019-01-10 | Natera, Inc. | Methods for simultaneous amplification of target loci |
| WO2011146632A1 (en) | 2010-05-18 | 2011-11-24 | Gene Security Network Inc. | Methods for non-invasive prenatal ploidy calling |
| US11326208B2 (en) | 2010-05-18 | 2022-05-10 | Natera, Inc. | Methods for nested PCR amplification of cell-free DNA |
| US10316362B2 (en) | 2010-05-18 | 2019-06-11 | Natera, Inc. | Methods for simultaneous amplification of target loci |
| US11332793B2 (en) | 2010-05-18 | 2022-05-17 | Natera, Inc. | Methods for simultaneous amplification of target loci |
| WO2012040603A2 (en) | 2010-09-23 | 2012-03-29 | Biocept, Inc. | Use of diazolidinyl urea for anti-clumping of biological samples |
| CN103608466B (zh) | 2010-12-22 | 2020-09-18 | 纳特拉公司 | 非侵入性产前亲子鉴定方法 |
| RU2671980C2 (ru) | 2011-02-09 | 2018-11-08 | Натера, Инк. | Способы неинвазивного пренатального установления плоидности |
| US9956281B2 (en) | 2011-05-04 | 2018-05-01 | Streck, Inc. | Inactivated virus compositions and methods of preparing such compositions |
| WO2012177656A2 (en) | 2011-06-19 | 2012-12-27 | Abogen, Inc. | Devices, solutions and methods for sample collection |
| CN113355321A (zh) | 2011-09-26 | 2021-09-07 | 凯杰有限公司 | 用于分离细胞外核酸的快速方法 |
| US11021733B2 (en) | 2011-09-26 | 2021-06-01 | Qiagen Gmbh | Stabilization and isolation of extracellular nucleic acids |
| ES2574956T3 (es) * | 2011-09-26 | 2016-06-23 | Preanalytix Gmbh | Estabilización y aislamiento de ácidos nucleicos extracelulares |
| ES2971646T3 (es) * | 2011-09-26 | 2024-06-06 | Preanalytix Gmbh | Estabilización y aislamiento de ácidos nucleicos extracelulares |
| US9416357B2 (en) | 2011-11-16 | 2016-08-16 | University Of Georgia Research Foundation, Inc. | Method for isolating total RNA from cells |
| WO2013123030A2 (en) * | 2012-02-13 | 2013-08-22 | Streck, Inc. | Blood collection device for improved nucleic acid regulation |
| DE102012101896A1 (de) * | 2012-03-06 | 2013-09-12 | Roberto Gerigk | Formalinfreie Fixierungsmittel für histologische Färbungen von Gewebeproben |
| US20140100126A1 (en) | 2012-08-17 | 2014-04-10 | Natera, Inc. | Method for Non-Invasive Prenatal Testing Using Parental Mosaicism Data |
| WO2014029792A1 (en) * | 2012-08-21 | 2014-02-27 | Qiagen Gmbh | Virus particle stabilisation and method for isolating viral nucleic acids |
| CA2884915C (en) | 2012-09-25 | 2022-05-17 | Qiagen Gmbh | Stabilisation of biological samples |
| CA2839051A1 (en) | 2013-01-14 | 2014-07-14 | Streck, Inc. | Blood collection device for stabilizing cell-free rna in blood during sample shipping and storage |
| WO2014145078A1 (en) | 2013-03-15 | 2014-09-18 | Verinata Health, Inc. | Generating cell-free dna libraries directly from blood |
| WO2014146782A1 (en) | 2013-03-18 | 2014-09-25 | Qiagen Gmbh | Stabilization and isolation of extracellular nucleic acids |
| EP2976424B1 (en) * | 2013-03-18 | 2018-10-03 | Qiagen GmbH | Stabilisation of biological samples |
| US10091984B2 (en) | 2013-07-24 | 2018-10-09 | Streck, Inc. | Compositions and methods for stabilizing circulating tumor cells |
| US9644232B2 (en) | 2013-07-26 | 2017-05-09 | General Electric Company | Method and device for collection and amplification of circulating nucleic acids |
| US9499870B2 (en) | 2013-09-27 | 2016-11-22 | Natera, Inc. | Cell free DNA diagnostic testing standards |
| US10262755B2 (en) | 2014-04-21 | 2019-04-16 | Natera, Inc. | Detecting cancer mutations and aneuploidy in chromosomal segments |
| US10577655B2 (en) | 2013-09-27 | 2020-03-03 | Natera, Inc. | Cell free DNA diagnostic testing standards |
| EP3102691B1 (en) | 2014-02-03 | 2019-09-11 | Thermo Fisher Scientific Baltics UAB | Method for controlled dna fragmentation |
| CN106132200B (zh) | 2014-03-18 | 2020-10-30 | 凯杰有限公司 | 胞外核酸的固定和分离 |
| US12492429B2 (en) | 2014-04-21 | 2025-12-09 | Natera, Inc. | Detecting mutations and ploidy in chromosomal segments |
| CA2945962C (en) | 2014-04-21 | 2023-08-29 | Natera, Inc. | Detecting mutations and ploidy in chromosomal segments |
| US20180173846A1 (en) | 2014-06-05 | 2018-06-21 | Natera, Inc. | Systems and Methods for Detection of Aneuploidy |
| ES2786373T3 (es) | 2014-06-10 | 2020-10-09 | Biomatrica Inc | Estabilización de trombocitos a temperaturas ambiente |
| CN106662512A (zh) * | 2014-06-10 | 2017-05-10 | 生物马特里卡公司 | 在环境温度下稳定血液样品中的非变性多肽、核酸和外来体 |
| ES2872344T3 (es) | 2014-07-02 | 2021-11-02 | Siemens Healthcare Diagnostics Inc | Separación selectiva de ácidos nucleicos |
| EP3169803B1 (en) | 2014-07-18 | 2019-11-20 | Illumina, Inc. | Non-invasive prenatal diagnosis of fetal genetic condition using cellular dna and cell free dna |
| EP3218523B1 (en) | 2014-11-14 | 2020-02-12 | Liquid Genomics Inc. | Use of circulating cell-free rna for diagnosis and/or monitoring cancer |
| US11168351B2 (en) | 2015-03-05 | 2021-11-09 | Streck, Inc. | Stabilization of nucleic acids in urine |
| US11479812B2 (en) | 2015-05-11 | 2022-10-25 | Natera, Inc. | Methods and compositions for determining ploidy |
| JP6787916B2 (ja) | 2015-06-10 | 2020-11-18 | キアゲン ゲーエムベーハー | アニオン交換粒子を使用する細胞外核酸を単離する方法 |
| ES2818569T3 (es) | 2015-09-09 | 2021-04-13 | Drawbridge Health Inc | Métodos para la recopilación, estabilización y conservación de muestras |
| US20170145475A1 (en) | 2015-11-20 | 2017-05-25 | Streck, Inc. | Single spin process for blood plasma separation and plasma composition including preservative |
| CN114457068B (zh) | 2015-11-20 | 2025-03-14 | 普瑞阿那利提克斯有限公司 | 用于稳定细胞外核酸的已灭菌组合物的制备方法 |
| KR20250047404A (ko) | 2015-12-08 | 2025-04-03 | 바이오매트리카 인코포레이티드 | 적혈구 침강 속도의 감소 |
| DE102016102346A1 (de) | 2016-02-10 | 2017-08-10 | Biosepar Gesellschaft für Medizin- und Labortechnik mbH | Fixativum |
| RU2760913C2 (ru) | 2016-04-15 | 2021-12-01 | Натера, Инк. | Способы выявления рака легкого |
| CN109153992B (zh) | 2016-05-27 | 2022-11-29 | 诺根生物科技公司 | 生物样本中游离核酸的保存 |
| WO2018022991A1 (en) | 2016-07-29 | 2018-02-01 | Streck, Inc. | Suspension composition for hematology analysis control |
| WO2018035340A1 (en) | 2016-08-17 | 2018-02-22 | The Regents Of The University Of California | A novel immunoprobe-based method to assess organ injury status through a biofluid-based cell-free dna (cfdna) assay |
| WO2018067517A1 (en) | 2016-10-04 | 2018-04-12 | Natera, Inc. | Methods for characterizing copy number variation using proximity-litigation sequencing |
| GB201618485D0 (en) | 2016-11-02 | 2016-12-14 | Ucl Business Plc | Method of detecting tumour recurrence |
| US10011870B2 (en) | 2016-12-07 | 2018-07-03 | Natera, Inc. | Compositions and methods for identifying nucleic acid molecules |
| US20210072255A1 (en) | 2016-12-16 | 2021-03-11 | The Brigham And Women's Hospital, Inc. | System and method for protein corona sensor array for early detection of diseases |
| WO2018156418A1 (en) | 2017-02-21 | 2018-08-30 | Natera, Inc. | Compositions, methods, and kits for isolating nucleic acids |
| US11795192B2 (en) | 2017-03-10 | 2023-10-24 | Lakewood Amedex, Inc. | Antimicrobial compounds, compositions, and uses thereof |
| SG11201908129PA (en) * | 2017-03-17 | 2019-10-30 | Nantomics Llc | LIQUID BIOPSY FOR cfRNA |
| CN110869518A (zh) * | 2017-05-16 | 2020-03-06 | 香港中文大学 | 整合式单细胞和游离血浆rna分析 |
| AU2018277094A1 (en) | 2017-06-01 | 2020-01-02 | Nantomics, Llc | DNA stabilization of RNA |
| BR112020001091A2 (pt) * | 2017-08-02 | 2020-09-15 | Sarstedt Ag & Co. Kg | processo e composição para a estabilização de ácidos nucleicos livres de células |
| CN115119829B (zh) * | 2017-10-19 | 2024-07-12 | 斯特雷克股份有限公司 | 用于胞外囊泡的溶血和凝血调节以及稳定化的组合物 |
| US11702703B2 (en) | 2017-11-07 | 2023-07-18 | Nanthealth Labs, Inc. | Targeted cell free nucleic acid analysis |
| US12084720B2 (en) | 2017-12-14 | 2024-09-10 | Natera, Inc. | Assessing graft suitability for transplantation |
| CN108103054B (zh) * | 2017-12-28 | 2020-10-02 | 广州市金圻睿生物科技有限责任公司 | 一种rna保存液及其用途 |
| CN108085391B (zh) * | 2017-12-28 | 2021-01-19 | 广州市金圻睿生物科技有限责任公司 | 一种可稳定保存的肺癌融合基因检测试剂盒的rna质控品 |
| CN108220478B (zh) * | 2017-12-28 | 2021-08-17 | 广州市金圻睿生物科技有限责任公司 | 可稳定保存的丙型肝炎病毒基因检测试剂盒的病毒质控品 |
| CN108048529B (zh) * | 2017-12-28 | 2021-01-19 | 广州市金圻睿生物科技有限责任公司 | 一种可稳定保存的肺癌甲基化基因检测试剂盒的质控品及应用 |
| CN108220417B (zh) * | 2017-12-28 | 2021-08-13 | 广州市金圻睿生物科技有限责任公司 | 可稳定保存的染色体非整倍体检测试剂盒的质控品及应用 |
| US12398389B2 (en) | 2018-02-15 | 2025-08-26 | Natera, Inc. | Methods for isolating nucleic acids with size selection |
| US12024738B2 (en) | 2018-04-14 | 2024-07-02 | Natera, Inc. | Methods for cancer detection and monitoring |
| WO2019210306A1 (en) * | 2018-04-27 | 2019-10-31 | Momenta Pharmaceuticals , Inc. | Blood preparation |
| CN108893524A (zh) * | 2018-06-04 | 2018-11-27 | 北京启衡星生物科技有限公司 | 血浆中游离dna的保护剂 |
| US12234509B2 (en) | 2018-07-03 | 2025-02-25 | Natera, Inc. | Methods for detection of donor-derived cell-free DNA |
| WO2020021119A1 (en) | 2018-07-27 | 2020-01-30 | F. Hoffmann-La Roche Ag | Method of monitoring effectiveness of immunotherapy of cancer patients |
| US20210280270A1 (en) | 2018-09-07 | 2021-09-09 | Illumina, Inc. | Method to determine if a circulating fetal cell isolated from a pregnant mother is from either the current or a historical pregnancy |
| KR20260016611A (ko) | 2018-11-07 | 2026-02-03 | 시어 인코퍼레이티드 | 단백질 코로나 분석을 위한 조성물, 방법 및 시스템 및 그것들의 용도 |
| CA3124698A1 (en) | 2018-12-27 | 2020-07-02 | Streck, Inc. | Methods of preparing samples for proteomic analysis |
| CN111378708B (zh) * | 2018-12-28 | 2022-07-19 | 康码（上海）生物科技有限公司 | 一种体外无细胞蛋白合成体系及其应用 |
| JP7518852B2 (ja) | 2019-03-26 | 2024-07-18 | シアー， インコーポレイテッド | 生物流体からのタンパク質コロナ分析のための組成物、方法およびシステム、ならびにそれらの使用 |
| US12305235B2 (en) | 2019-06-06 | 2025-05-20 | Natera, Inc. | Methods for detecting immune cell DNA and monitoring immune system |
| CN110747193B (zh) * | 2019-09-25 | 2021-08-31 | 广州市达瑞生物技术股份有限公司 | 一种基于二代测序平台的肺癌多基因联合检测试剂盒质控品 |
| CN111117999A (zh) * | 2019-12-18 | 2020-05-08 | 上海兰卫医学检验所股份有限公司 | 一种适用于液态活检技术的血浆exRNA提取保存方法 |
| EP4660324A3 (en) * | 2020-02-24 | 2026-02-18 | The Board of Trustees of the Leland Stanford Junior University | Methods of analyzing cell free nucleic acids and applications thereof |
| CN116157681A (zh) | 2020-07-01 | 2023-05-23 | 斯特雷克股份有限公司 | 制备用于蛋白质组学分析的样品的方法 |
| WO2022011182A1 (en) * | 2020-07-10 | 2022-01-13 | Acutis Diagnostics, Inc. | Methods and compositions for isolation and rapid detection of micro-organisms from blood and bodily fluids |
| US20230302454A1 (en) | 2020-08-13 | 2023-09-28 | Streck, Inc. | Sample collection containers, processes and collected samples |
| CN112251358A (zh) * | 2020-10-23 | 2021-01-22 | 瑞因迈拓科技(广州)有限公司 | 一种用于病原微生物检测体液标本的保存剂及其应用 |
| CN112501159A (zh) * | 2020-12-04 | 2021-03-16 | 麦凯(上海)生物科技有限公司 | 一种通用型游离核酸保护剂 |
| EP4263383A4 (en) | 2020-12-17 | 2024-10-23 | Nephrosant, Inc. | KITS FOR STABILIZATION OF URINE SAMPLES |
| WO2022150283A1 (en) * | 2021-01-05 | 2022-07-14 | Nuclease Probe Technologies, Inc. | Sars-cov-2 detection |
| CN112760360B (zh) * | 2021-03-22 | 2023-12-19 | 洛阳赛奥生物工程技术有限公司 | 一种rna保护剂及其应用 |
| JP7310055B1 (ja) * | 2021-08-25 | 2023-07-24 | 積水メディカル株式会社 | 細胞含有液用保存液及び細胞含有液用保存容器 |
| AU2023298557A1 (en) * | 2022-06-29 | 2025-01-16 | Life Technologies Corporation | Systems and methods for analyte detection from multiplexed assays |
| KR102699668B1 (ko) * | 2022-07-22 | 2024-08-28 | 주식회사 어큐진 | 분변 rna 보존액 |
| EP4356731A1 (en) * | 2022-10-19 | 2024-04-24 | Olga Alekseevna Gra | Medium and device for collecting, storing and transporting biological samples, as well as their use for the stabilization of extracellular nucleic acids |
| GB202303562D0 (en) | 2023-03-10 | 2023-04-26 | Belgian Volition Sprl | Sample collection for liquid biopsy |
| WO2024192232A1 (en) | 2023-03-14 | 2024-09-19 | Streck Llc | Compositions and uses thereof for stabilization of blood sample components |
| WO2025167593A1 (zh) * | 2024-02-06 | 2025-08-14 | 上海细胞治疗集团股份有限公司 | 生物样本的存储保护剂、采集卡、存储和检测方法 |
Citations (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5196182A (en) | 1991-05-08 | 1993-03-23 | Streck Laboratories, Inc. | Tissue fixative |
| US5213765A (en) | 1990-04-27 | 1993-05-25 | Terumo Kabushiki Kaisha | Blood collection tube |
| US5257633A (en) | 1992-06-23 | 1993-11-02 | Becton, Dickinson And Company | Surface modified blood collection tubes |
| US5260048A (en) | 1991-05-08 | 1993-11-09 | Streck Laboratories, Inc. | Tissue fixative solution and method |
| US5459073A (en) | 1991-05-08 | 1995-10-17 | Streck Laboratories, Inc. | Method and composition for preserving antigens and process for utilizing cytological material produced by same |
| US5614391A (en) | 1991-07-19 | 1997-03-25 | Pharmacia P.L. Biochemicals, Inc. | m-RNA purification |
| US5811099A (en) | 1991-05-08 | 1998-09-22 | Streck Laboratories, Inc. | Method and composition for preserving antigens and process for utilizing cytological material produced by same |
| US5849517A (en) | 1991-05-08 | 1998-12-15 | Streck Laboratories, Inc. | Method and composition for preserving antigens and nucleic acids and process for utilizing cytological material produced by same |
| US5985572A (en) | 1993-02-01 | 1999-11-16 | Qiagen N.V. | Quaternary amine surfactant and methods of using same in isolation of RNA |
| US6077235A (en) | 1999-02-23 | 2000-06-20 | Becton, Dickinson And Company | Blood collection assembly and method therefor |
| US6337189B1 (en) | 2000-02-08 | 2002-01-08 | Streck Laboratories, Inc. | Fixative system, method and composition for biological testing |
| US6551267B1 (en) | 2000-10-18 | 2003-04-22 | Becton, Dickinson And Company | Medical article having blood-contacting surface |
| US6617170B2 (en) | 2000-11-08 | 2003-09-09 | Becton, Dickinson And Company | Method and device for collecting and stabilizing a biological sample |
| US6630301B1 (en) | 1997-03-14 | 2003-10-07 | The Penn State Research Foundation | Detection of extracellular tumor-associated nucleic acid in blood plasma or serum |
| US6759217B2 (en) | 1996-03-26 | 2004-07-06 | Oncomedx, Inc. | Method enabling use of extracellular RNA extracted from plasma or serum to detect, monitor or evaluate cancer |
| US20040137417A1 (en) | 2002-10-16 | 2004-07-15 | Streck Laboratories Inc. | Method and device for collecting and preserving cells for analysis |
| US6821789B2 (en) | 2000-11-08 | 2004-11-23 | Becton, Dickinson And Company | Method and device for collecting and stabilizing a biological sample |
| US6916634B2 (en) | 1996-03-26 | 2005-07-12 | Oncomedx, Inc. | Method enabling use of extracellular RNA extracted from plasma or serum to detect, monitor or evaluate cancer |
| US6939675B2 (en) | 1996-03-15 | 2005-09-06 | The Penn State Research Foundation | Detection of extracellular tumor-associated nucleic acid in blood plasma or serum using nucleic acid amplification assays |
| US20080096217A1 (en) | 2001-07-25 | 2008-04-24 | Oncomedx Inc. | Methods for evaluating pathologic conditions using extracellular RNA |
| US7390663B2 (en) | 2005-02-23 | 2008-06-24 | Streck, Inc. | Process, composition and kit for providing a stable whole blood calibrator/control |
| US7419832B2 (en) | 2005-03-10 | 2008-09-02 | Streck, Inc. | Blood collection tube with surfactant |
| US20080261292A1 (en) | 1998-09-22 | 2008-10-23 | Oncomedx, Inc. | Method Enabling the Use of Extracellular Ribonucleic Acid (RNA) Extracted from Plasma or Serum to Detect, Monitor or Evaluate Cancer or Premalignant Conditions |
| US20090081678A1 (en) | 2007-09-21 | 2009-03-26 | Streck, Inc. | Nucleic acid isolation in preserved whole blood |
| WO2010004474A2 (en) | 2008-07-10 | 2010-01-14 | Rocketic Technologies Ltd | Efficient parallel computation of dependency problems |
| WO2010096323A1 (en) | 2009-02-18 | 2010-08-26 | Streck, Inc. | Preservation of cell-free nucleic acids |
Family Cites Families (166)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US1432249A (en) | 1922-02-06 | 1922-10-17 | Howard S Borden | Article of manufacture |
| US1922799A (en) * | 1932-12-16 | 1933-08-15 | George E Gaus | Method for affixing identification tags |
| US2250666A (en) * | 1938-10-31 | 1941-07-29 | Godefroy Mfg Company | Combined label, cap loosener, and auxiliary container |
| US2690624A (en) | 1949-09-15 | 1954-10-05 | Ollie W Phillips | Sign |
| US2930570A (en) * | 1959-01-30 | 1960-03-29 | Herbert R Leedy | Pinch clamp |
| US3867521A (en) | 1970-08-26 | 1975-02-18 | Scherer Corp R P | Method for absorption of drugs |
| US3781120A (en) | 1970-09-14 | 1973-12-25 | Technicon Instr | Self-locating sample receptacle having integral identification label |
| US3874384A (en) | 1971-11-01 | 1975-04-01 | American Hospital Supply Corp | Improved blood storage unit and method of storing blood |
| US3872730A (en) | 1972-03-10 | 1975-03-25 | Becton Dickinson Co | Sampling apparatus |
| US3879295A (en) | 1973-08-17 | 1975-04-22 | Eastman Kodak Co | Vacutainer with positive separation barrier |
| US3973913A (en) | 1976-01-29 | 1976-08-10 | Louderback Allan Lee | Blood control standard |
| US3994085A (en) | 1976-03-29 | 1976-11-30 | Groselak Robert E | Baggage tag |
| US4043453A (en) * | 1976-05-11 | 1977-08-23 | The Wright Tool & Forge Company | Holder and display device for wrench sockets |
| US4318090A (en) * | 1980-10-27 | 1982-03-02 | Sensormatic Electronics Corporation | Apparatus for deactivating a surveillance tag |
| US4513522A (en) * | 1982-09-16 | 1985-04-30 | Selenke William M | Label with particular application to laboratory specimen container identification |
| US4515890A (en) | 1982-11-08 | 1985-05-07 | Abbott Laboratories | Immunoassay of terminal deoxynucleotidyl transferase |
| DE8407967U1 (de) * | 1984-03-15 | 1984-06-07 | Idento - Gesellschaft für industrielle Kennzeichnung mbH, 6074 Rödermark | Beschriftbarer Kabelmarkierungsstreifen |
| US4584219A (en) * | 1984-11-09 | 1986-04-22 | Baartmans Hans R | Web of labels |
| US4675159A (en) | 1985-09-29 | 1987-06-23 | Al Sioufi Habib | Method and device for disinfecting biological fluids and container for same |
| US5110908A (en) | 1986-12-31 | 1992-05-05 | Praxis Biologics, Inc. | Haemophilus influenzae peptides and proteins |
| US4884827A (en) | 1988-01-22 | 1989-12-05 | Norfolk Scientific Inc. | Partially transparent label |
| US4921277A (en) * | 1988-10-24 | 1990-05-01 | Academy Of Applied Science, Inc. | Method of labeling needle syringes and medication vials and novel labels therefor |
| HU201865B (en) | 1989-04-28 | 1991-01-28 | Pecsi Dohanygyar | Tobacco-smoke filter of high efficiency |
| US5000484A (en) * | 1989-08-30 | 1991-03-19 | Phelan James C | Identification and monitoring system for surgical specimens |
| US5153117A (en) * | 1990-03-27 | 1992-10-06 | Genetype A.G. | Fetal cell recovery method |
| US5250438A (en) | 1990-05-09 | 1993-10-05 | Streck Laboratories, Inc. | Method for differential determination of white blood cells using diazolidinyl urea to stabilize white blood cells |
| US5135125A (en) * | 1991-02-15 | 1992-08-04 | Tapecon, Inc. | Hanging label |
| US5343647A (en) * | 1991-09-03 | 1994-09-06 | Moore Business Forms, Inc. | Pressure sensitive pricing tag/label |
| EP0627879A1 (en) | 1991-09-20 | 1994-12-14 | CAMIENER, Gerald, W. | Methods and compositions with aldehyde stabilizing solution |
| US5998483A (en) | 1991-09-20 | 1999-12-07 | Camiener; Gerald W. | Glyoxal-containing preservative compositions |
| DE4134231A1 (de) | 1991-10-16 | 1993-04-22 | Fix Gmbh | Gepaeckstreifenanhaenger fuer einzelbeschriftung |
| US5629147A (en) * | 1992-07-17 | 1997-05-13 | Aprogenex, Inc. | Enriching and identifying fetal cells in maternal blood for in situ hybridization |
| BR9306867A (pt) | 1992-07-17 | 1998-12-08 | Aprogenex Inc | Enriquecimento e identificação de células fetais do sangue materno para a hibridização in situ |
| GB9223035D0 (en) | 1992-11-03 | 1992-12-16 | Kiessling Cooper Ann A | Preservation of peripheral blood & semen in fixatives that inactivate human pathogens |
| US5688516A (en) | 1992-11-12 | 1997-11-18 | Board Of Regents, The University Of Texas System | Non-glycopeptide antimicrobial agents in combination with an anticoagulant, an antithrombotic or a chelating agent, and their uses in, for example, the preparation of medical devices |
| AU669754B2 (en) | 1992-12-18 | 1996-06-20 | Becton Dickinson & Company | Barrier coating |
| US5457024A (en) | 1993-01-22 | 1995-10-10 | Aprogenex, Inc. | Isolation of fetal erythrocytes |
| ES2197168T3 (es) * | 1993-07-05 | 2004-01-01 | Sheffield Teaching Hospitals National Health Service Trust | Preparacion y estabilizacion de celulas. |
| US6043032A (en) * | 1993-09-22 | 2000-03-28 | Tosoh Corporation | Method of extracting nucleic acids and method of detecting specified nucleic acid sequences |
| JPH09510875A (ja) | 1994-03-29 | 1997-11-04 | ジェンザイム・コーポレイション | 母親の末梢血からの胎児細胞の培養および単離 |
| CN1149338A (zh) * | 1994-04-05 | 1997-05-07 | 北方总医院N·H·S·托拉斯 | 细胞悬浮液的制备和稳定化 |
| US5501954A (en) * | 1994-06-13 | 1996-03-26 | Genzyme Corporation | Method of detecting cellular material |
| US5468022A (en) | 1994-06-14 | 1995-11-21 | Massachusetts Institute Of Technology | Sample tube identification flag |
| FR2722506B1 (fr) * | 1994-07-13 | 1996-08-14 | Rhone Poulenc Rorer Sa | Composition contenant des acides nucleiques, preparation et utilisations |
| US5512343A (en) * | 1994-08-01 | 1996-04-30 | Diagraph Corporation | Label assembly |
| US5540358A (en) * | 1994-12-19 | 1996-07-30 | The Procter And Gamble Company | Flexible planar gusseted package for dispensing a product through a fitment |
| US5490658A (en) * | 1995-03-02 | 1996-02-13 | Avery Dennison Corporation | Label hangers for intravenous bottles |
| US5560657A (en) | 1995-03-08 | 1996-10-01 | Morgan; Brian R. | Tamper-indicating label |
| USD382343S (en) * | 1995-06-06 | 1997-08-12 | Home Access Health Corporation | Filmstrip for enhancing blood flow |
| US6527957B1 (en) * | 1995-08-09 | 2003-03-04 | Baxter International Inc. | Methods for separating, collecting and storing red blood cells |
| US5817519A (en) | 1995-12-28 | 1998-10-06 | Bayer Corporation | Automated method and device for identifying and quantifying platelets and for determining platelet activation state using whole blood samples |
| US6072086A (en) | 1996-04-12 | 2000-06-06 | Intergen Company | Method and composition for controlling formaldehyde fixation by delayed quenching |
| GB2313288B (en) * | 1996-05-24 | 2000-07-12 | North Gen Hospital Nhs Trust | Specimen collection fluid |
| IT1294964B1 (it) | 1996-07-12 | 1999-04-23 | Domenico Valerio | Isolamento e cultura di cellule fetali dal sangue periferico materno |
| US6074827A (en) | 1996-07-30 | 2000-06-13 | Aclara Biosciences, Inc. | Microfluidic method for nucleic acid purification and processing |
| US5731156A (en) * | 1996-10-21 | 1998-03-24 | Applied Imaging, Inc. | Use of anti-embryonic hemoglobin antibodies to identify fetal cells |
| US6190609B1 (en) * | 1996-11-19 | 2001-02-20 | Baxter International Inc. | Methods and apparatus for inactivating contaminants in biological fluid |
| US5783093A (en) * | 1997-01-02 | 1998-07-21 | Haemonetics Corporation | Blood cell concentrates using a single solution for anticoagulation and preservation |
| WO1998031219A1 (en) * | 1997-01-21 | 1998-07-23 | The American National Red Cross | Intracellular and extracellular decontamination of whole blood and blood components by amphiphilic phenothiazin-5-ium dyes plus light |
| US6125563A (en) | 1997-02-14 | 2000-10-03 | Girerd; Philippe H. | Container label with handle flap |
| US20010051341A1 (en) | 1997-03-04 | 2001-12-13 | Isis Innovation Limited | Non-invasive prenatal diagnosis |
| GB9704444D0 (en) * | 1997-03-04 | 1997-04-23 | Isis Innovation | Non-invasive prenatal diagnosis |
| ATE251306T1 (de) * | 1997-03-25 | 2003-10-15 | Immunivest Corp | Gerät und methoden zum einfnag und zur analyse von partikel-einheiten |
| SE514350C2 (sv) * | 1997-04-07 | 2001-02-12 | Resemino System Ab | Metod för affischering samt för metoden anpassat system för affischering |
| US5939259A (en) * | 1997-04-09 | 1999-08-17 | Schleicher & Schuell, Inc. | Methods and devices for collecting and storing clinical samples for genetic analysis |
| US5906744A (en) | 1997-04-30 | 1999-05-25 | Becton Dickinson And Company | Tube for preparing a plasma specimen for diagnostic assays and method of making thereof |
| US5976014A (en) | 1997-05-28 | 1999-11-02 | Moore U.S.A., Inc. | Integrity seal form/label combination |
| US6251638B1 (en) * | 1997-05-30 | 2001-06-26 | Diagen Corporation | Methods for detection of nucleic acid sequences in urine |
| US6083731A (en) * | 1997-06-24 | 2000-07-04 | Washington State University Research Foundation | Recombinant materials and methods for the production of limonene hydroxylases |
| WO1998059076A1 (en) * | 1997-06-25 | 1998-12-30 | Promega Corporation | Method of isolating rna |
| US5962234A (en) | 1997-10-20 | 1999-10-05 | Applied Imaging Corporation | Use of anti-embryonic epsilon hemoglobin antibodies to identify fetal cells |
| CA2260402C (en) | 1998-01-22 | 2001-10-23 | Pierre Boisvert | Display card |
| US6210889B1 (en) * | 1998-01-28 | 2001-04-03 | The Universite Laval | Method for enrichment of fetal cells from maternal blood and use of same in determination of fetal sex and detection of chromosomal abnormalities |
| US20010018192A1 (en) * | 1998-02-12 | 2001-08-30 | Terstappen Leon W.M.M. | Labeled cells for use as an internal functional control in rare cell detection assays |
| BR9907852A (pt) | 1998-02-12 | 2000-10-24 | Immunivest Corp | Processos para detectar e enumerar células raras e cancerosas em uma população celular mista, para diagnosticar câncer de estágio precoce em um paciente de teste, para determinar a probabilidade de recorrência de câncer em um paciente humano anteriormente tratado de câncer, para distinguir um carcinoma confinado ao órgão de um carcinoma com propriedades metastáticas, para acompanhar a situação de remissão em um paciente humano com câncer que passa pelo tratamento de terapia contra o câncer e para aumentar quantidades de células epiteliais circulantes em uma amostra de sangue, partìcula magnética revestida, composição, conjuntos de teste para avaliar uma amostra de paciente quanto a presença de células raras circulantes, quanto a presença de células de tumor circulantes, quanto a presença de células de câncer de mama circulantes, quanto a presença de células de câncer de próstata circulantes, quanto a presença de células de câncer de cólon circulantes, quanto a presença de células de câncer de bexiga circulantes e para monitorar um paciente quanto a recorrência de câncer, e, fração de sangue periférico enriquecido quanto a células neoplásticas circulantes |
| US6177163B1 (en) * | 1998-06-22 | 2001-01-23 | Tricor Direct, Inc. | Markable repositionable adhesive sheet dispensing roll for use in an industrial setting |
| US6204375B1 (en) * | 1998-07-31 | 2001-03-20 | Ambion, Inc. | Methods and reagents for preserving RNA in cell and tissue samples |
| US20060204989A1 (en) * | 1998-09-22 | 2006-09-14 | Kopreski Michael S | Comparative analysis of extracellular RNA species |
| US7683035B1 (en) | 1999-02-23 | 2010-03-23 | Qiagen, Gmbh | Method of stabilizing and/or isolating nucleic acids |
| EP1203227A4 (en) | 1999-06-04 | 2003-01-02 | Bioseparations Inc | PRENATAL DIAGNOSIS SCREENING SYSTEM AND METHOD |
| WO2000077235A1 (en) | 1999-06-16 | 2000-12-21 | University Of Cincinnati | Agent and process for isolation of extra-chromosomal nucleic acids |
| DE19928820A1 (de) | 1999-06-17 | 2000-12-21 | Ulrich Groth | Fixiermittel für Zellen und Gewebe von Lebewesen |
| CA2373689A1 (en) * | 1999-07-29 | 2001-02-08 | Thomas W. Coneys | Sampling tube holder for blood sampling system |
| DE60044977D1 (de) | 1999-09-24 | 2010-10-28 | Ambion Inc | Cocktail von nukleaseinhibitoren |
| US20010049895A1 (en) | 2000-01-06 | 2001-12-13 | Burke Doyle G. | Promotional hanger |
| DE10006662A1 (de) | 2000-02-15 | 2001-08-23 | Antigen Produktions Gmbh | Gefäß zur Nukleinsäureanalytik |
| GB0009179D0 (en) | 2000-04-13 | 2000-05-31 | Imp College Innovations Ltd | Non-invasive prenatal diagnosis |
| GB0009784D0 (en) | 2000-04-20 | 2000-06-07 | Simeg Limited | Methods for clinical diagnosis |
| US20020045196A1 (en) * | 2000-05-12 | 2002-04-18 | Walt Mahoney | Methods of isolating trophoblast cells from maternal blood |
| US6860513B2 (en) * | 2000-06-08 | 2005-03-01 | Scriptchek Visual Verification Systems, Inc. | Verification of prescription information and warning label |
| ATE466930T1 (de) * | 2000-06-21 | 2010-05-15 | Qiagen Gaithersburg Inc | Universelles sammelmedium |
| US6813868B2 (en) * | 2000-08-10 | 2004-11-09 | Baxa Corporation | Method, system, and apparatus for handling, labeling, filling and capping syringes |
| US6664056B2 (en) | 2000-10-17 | 2003-12-16 | The Chinese University Of Hong Kong | Non-invasive prenatal monitoring |
| AU1179502A (en) | 2000-10-17 | 2002-04-29 | Impath Inc | Nucleic acid amplification controls |
| CA2428757A1 (en) | 2000-11-15 | 2002-07-18 | Roche Diagnostics Corporation | Methods and reagents for identifying rare fetal cells in the maternal circulation |
| EP1207208A3 (en) | 2000-11-15 | 2003-12-10 | Becton Dickinson and Company | Method for preservation of cells and nucleic acid targets |
| US20020066216A1 (en) * | 2000-12-01 | 2002-06-06 | Delacruz Cedric G. | Baby birth announcement |
| US6794152B2 (en) * | 2000-12-22 | 2004-09-21 | Streck Laboratories Inc. | Flow cytometry reagent and system |
| US6581973B2 (en) * | 2001-03-30 | 2003-06-24 | Cheringal Associates, Inc. | Double blind study label |
| US6617180B1 (en) * | 2001-04-16 | 2003-09-09 | Taiwan Semiconductor Manufacturing Company | Test structure for detecting bridging of DRAM capacitors |
| FR2824144B1 (fr) * | 2001-04-30 | 2004-09-17 | Metagenex S A R L | Methode de diagnostic prenatal sur cellule foetale isolee du sang maternel |
| WO2008111981A1 (en) | 2007-03-14 | 2008-09-18 | Sierra Molecular Corporation | Compositions, systems, and methods for preservation of macromolecules |
| WO2003019141A2 (en) | 2001-08-23 | 2003-03-06 | Immunivest Corporation | Analysis of circulating tumor cells, fragments, and debris |
| US7863012B2 (en) | 2004-02-17 | 2011-01-04 | Veridex, Llc | Analysis of circulating tumor cells, fragments, and debris |
| US6884573B2 (en) * | 2001-08-31 | 2005-04-26 | The University Of North Carolina At Chapel Hill | Fixed dried red blood cells and method of use |
| US6527242B1 (en) * | 2001-10-01 | 2003-03-04 | Netta Kennedy | Brace for a picture frame |
| WO2003063930A1 (en) * | 2002-02-01 | 2003-08-07 | Gambro, Inc. | Whole blood collection and processing method |
| GB0203280D0 (en) * | 2002-02-12 | 2002-03-27 | Ic Innovations Ltd | Anti-glycolytic composition |
| CA2515243A1 (en) | 2002-02-22 | 2003-08-28 | Klaus Strebhardt | Agent for inhibiting development or progress of proliferative diseases and especially cancer diseases and pharmaceutical composition containing said agent |
| GB2386038A (en) | 2002-02-27 | 2003-09-03 | Motorola Inc | Channel estimation in a radio receiver |
| US6977162B2 (en) * | 2002-03-01 | 2005-12-20 | Ravgen, Inc. | Rapid analysis of variations in a genome |
| WO2003095974A2 (en) | 2002-05-07 | 2003-11-20 | Becton, Dickinson And Company | Collection assembly |
| US20070178478A1 (en) * | 2002-05-08 | 2007-08-02 | Dhallan Ravinder S | Methods for detection of genetic disorders |
| US7442506B2 (en) | 2002-05-08 | 2008-10-28 | Ravgen, Inc. | Methods for detection of genetic disorders |
| US7022478B2 (en) * | 2002-05-14 | 2006-04-04 | The Chinese University Of Hong Kong | Methods for evaluating stroke or cardiac ischemia by nucleic acid detection |
| WO2003099957A1 (en) | 2002-05-22 | 2003-12-04 | Duke University | Rnp immunoprecipitation assay |
| WO2003106623A2 (en) | 2002-06-13 | 2003-12-24 | New York University | Early noninvasive prenatal test for aneuploidies and heritable conditions |
| US6913932B2 (en) * | 2002-08-23 | 2005-07-05 | Beckman Coulter, Inc. | Formaldehyde-ammonium salt complexes for the stabilization of blood cells |
| US20060008807A1 (en) * | 2002-08-23 | 2006-01-12 | O'hara Shawn M | Multiparameter analysis of comprehensive nucleic acids and morphological features on the same sample |
| EP1816461B1 (en) | 2002-10-16 | 2020-01-08 | Streck Laboratories, Inc. | Method and device for collecting and preserving cells for analysis |
| KR100471183B1 (ko) * | 2002-10-29 | 2005-03-10 | 삼성전자주식회사 | 오프 세트 트랜지스터를 갖는 반도체 기억소자 및 그제조방법 |
| EP1599608A4 (en) * | 2003-03-05 | 2007-07-18 | Genetic Technologies Ltd | Identification of fetal DNA and fetal cell marker in maternal plasma or serum |
| US7267980B1 (en) | 2003-04-04 | 2007-09-11 | Research & Diagnostic Systems, Inc. | Stabilizing solution for cells and tissues |
| US20050277204A1 (en) | 2003-08-12 | 2005-12-15 | Massachusetts Institute Of Technology | Sample preparation methods and devices |
| US7318293B2 (en) * | 2003-09-19 | 2008-01-15 | Ardern Ii William B | Binder clip sleeve |
| US20070111233A1 (en) * | 2003-10-30 | 2007-05-17 | Bianchi Diana W | Prenatal diagnosis using cell-free fetal DNA in amniotic fluid |
| US20050181353A1 (en) * | 2004-02-17 | 2005-08-18 | Rao Galla C. | Stabilization of cells and biological specimens for analysis |
| US20100216153A1 (en) | 2004-02-27 | 2010-08-26 | Helicos Biosciences Corporation | Methods for detecting fetal nucleic acids and diagnosing fetal abnormalities |
| US20080119645A1 (en) * | 2004-05-05 | 2008-05-22 | Isis Pharmaceuticals, Inc. | Amidites and Methods of Rna Synthesis |
| US8497134B2 (en) | 2004-08-19 | 2013-07-30 | Blood Cell Storage, Inc. | Fluorescent detector systems for the detection of chemical perturbations in sterile storage devices |
| ES2251307B2 (es) * | 2004-10-05 | 2006-12-16 | Universidad Complutense De Madrid | Solucion para el mantenimiento indefinido de los acidos nucleicos en su celula de origen. |
| US20060105372A1 (en) * | 2004-11-05 | 2006-05-18 | Bair Robert J | Compositions and methods for purifying nucleic acids from stabilization reagents |
| ATE481504T1 (de) | 2004-12-10 | 2010-10-15 | Siemens Healthcare Diagnostics | Für die vorhersage des ansprechens maligner neoplasie auf eine auf taxan beruhende medizinische behandlung geeignete genetische veränderung |
| DE102005013261A1 (de) | 2005-03-22 | 2006-09-28 | Adnagen Ag | Reagenz und Verfahren zur Verhinderung der zeitabhängigen Expression in biologischen Zellen |
| WO2007030163A2 (en) | 2005-05-20 | 2007-03-15 | Imaging Sciences International, Inc. | Panoramic view generator |
| WO2007022483A2 (en) | 2005-08-19 | 2007-02-22 | Bioventures, Inc. | Method and device for the collection and isolation of nucleic acid |
| WO2007053491A2 (en) | 2005-10-28 | 2007-05-10 | The Trustees Of Columbia University In The City Of New York | Method and kit for evaluating rna quality |
| EP3591068A1 (en) * | 2006-02-02 | 2020-01-08 | The Board of Trustees of the Leland Stanford Junior University | Non-invasive fetal genetic screening by digital analysis |
| EP2351858B1 (en) * | 2006-02-28 | 2014-12-31 | University of Louisville Research Foundation | Detecting fetal chromosomal abnormalities using tandem single nucleotide polymorphisms |
| US20070243548A1 (en) | 2006-03-28 | 2007-10-18 | Elias Georges | Calumenin-directed diagnostics and therapeutics for cancer and chemotherapeutic drug resistance |
| WO2007121276A2 (en) | 2006-04-12 | 2007-10-25 | Biocept, Inc. | Enrichment of circulating fetal dna |
| ES2264403B1 (es) | 2006-06-22 | 2007-11-01 | Grifols S.A. | Medio de suspension de hematies. |
| WO2008006086A2 (en) * | 2006-07-07 | 2008-01-10 | Atlantic City Coin & Slot Service Company, Inc. | Gaming device and method of use |
| WO2008028086A2 (en) | 2006-08-30 | 2008-03-06 | Bioventures, Inc. | Methods and substances for isolation and detection of small polynucleotides |
| US8080645B2 (en) | 2007-10-01 | 2011-12-20 | Longhorn Vaccines & Diagnostics Llc | Biological specimen collection/transport compositions and methods |
| US20080108071A1 (en) * | 2006-10-10 | 2008-05-08 | Katherine Thompson | Methods and Systems to Determine Fetal Sex and Detect Fetal Abnormalities |
| GB0704488D0 (en) * | 2007-03-08 | 2007-04-18 | Univ Nottingham | Platelet viability kit |
| US8537789B2 (en) | 2007-08-01 | 2013-09-17 | Harris Corporation | Mobile ad-hoc network providing communication latency reduction features and related methods |
| US20090308303A1 (en) | 2008-06-13 | 2009-12-17 | Burlando Albert A | Identification marker |
| WO2010078194A1 (en) * | 2008-12-30 | 2010-07-08 | Streck, Inc. | Method for screening blood using a preservative that may be in a substantially solid state form |
| US11634747B2 (en) * | 2009-01-21 | 2023-04-25 | Streck Llc | Preservation of fetal nucleic acids in maternal plasma |
| AU2010229924B2 (en) | 2009-03-24 | 2016-07-21 | Plus Therapeutics Inc. | Devices and methods of cell capture and analysis |
| US20110027771A1 (en) * | 2009-07-31 | 2011-02-03 | Artemis Health, Inc. | Methods and compositions for cell stabilization |
| US20110053208A1 (en) * | 2009-08-31 | 2011-03-03 | Streck, Inc. | Biological sample identification system |
| US20110111410A1 (en) * | 2009-11-09 | 2011-05-12 | Streck, Inc. | Stabilization of rna in intact cells within a blood sample |
| AU2011203450B2 (en) | 2010-01-04 | 2016-01-07 | Qiagen Gaithersburg, Inc. | Methods, compositions, and kits for recovery of nucleic acids or proteins from fixed tissue samples |
| WO2012040603A2 (en) | 2010-09-23 | 2012-03-29 | Biocept, Inc. | Use of diazolidinyl urea for anti-clumping of biological samples |
| JP2013539190A (ja) | 2010-10-07 | 2013-10-17 | ショット アクチエンゲゼルシャフト | 電気化学的エネルギー電池に使われるセパレータを製造するためのガラス系材料 |
| EP2642145A4 (en) | 2010-11-16 | 2015-10-21 | Ntn Toyo Bearing Co Ltd | BALL BEARING, AND METHOD FOR PRODUCING BALL BEARING |
| CA2830389A1 (en) | 2011-04-21 | 2012-10-26 | Streck, Inc. | Improved sample tube having particular utility for nucleic acid amplification |
| WO2012166913A1 (en) | 2011-06-01 | 2012-12-06 | Streck, Inc. | Rapid thermocycler system for rapid amplification of nucleic acids and related methods |
| CA2858689A1 (en) | 2011-12-09 | 2013-06-13 | The Scripps Research Institute | Apparatus, system and method for identifying circulating tumor cells |
| WO2013123030A2 (en) | 2012-02-13 | 2013-08-22 | Streck, Inc. | Blood collection device for improved nucleic acid regulation |
| EP2888363B1 (en) | 2012-08-21 | 2018-06-06 | Qiagen GmbH | Method for isolating nucleic acids from a formaldehyde releaser stabilized sample |
| CA2839051A1 (en) | 2013-01-14 | 2014-07-14 | Streck, Inc. | Blood collection device for stabilizing cell-free rna in blood during sample shipping and storage |
| US10091984B2 (en) | 2013-07-24 | 2018-10-09 | Streck, Inc. | Compositions and methods for stabilizing circulating tumor cells |
-
2010
- 2010-02-11 NO NO10704474A patent/NO2398912T3/no unknown
- 2010-02-11 EP EP20193258.9A patent/EP3778919A1/en not_active Withdrawn
- 2010-02-11 WO PCT/US2010/023859 patent/WO2010096323A1/en not_active Ceased
- 2010-02-11 EP EP17185367.4A patent/EP3290530B1/en active Active
- 2010-02-11 US US12/704,030 patent/US8304187B2/en active Active
- 2010-02-11 EP EP10704474.5A patent/EP2398912B1/en not_active Not-in-force
- 2010-02-11 DK DK17185367.4T patent/DK3290530T3/da active
- 2010-02-11 DE DE202010018569.6U patent/DE202010018569U1/de not_active Expired - Lifetime
- 2010-02-11 ES ES10704474.5T patent/ES2649572T3/es active Active
- 2010-02-11 DK DK10704474.5T patent/DK2398912T3/en active
-
2012
- 2012-10-10 US US13/648,415 patent/US8586306B2/en not_active Expired - Fee Related
-
2013
- 2013-11-05 US US14/071,969 patent/US9657227B2/en active Active
-
2017
- 2017-05-22 US US15/601,682 patent/US9926590B2/en active Active
-
2018
- 2018-02-12 US US15/894,077 patent/US10144955B2/en active Active
- 2018-03-27 US US15/937,446 patent/US10294513B2/en active Active
-
2019
- 2019-04-08 US US16/377,344 patent/US10689686B2/en active Active
-
2020
- 2020-06-22 US US16/908,233 patent/US11761025B2/en active Active
-
2023
- 2023-07-31 US US18/228,306 patent/US20230374568A1/en not_active Abandoned
-
2024
- 2024-03-15 US US18/606,919 patent/US20240218425A1/en not_active Abandoned
Patent Citations (32)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5213765A (en) | 1990-04-27 | 1993-05-25 | Terumo Kabushiki Kaisha | Blood collection tube |
| US5196182A (en) | 1991-05-08 | 1993-03-23 | Streck Laboratories, Inc. | Tissue fixative |
| US5260048A (en) | 1991-05-08 | 1993-11-09 | Streck Laboratories, Inc. | Tissue fixative solution and method |
| US5459073A (en) | 1991-05-08 | 1995-10-17 | Streck Laboratories, Inc. | Method and composition for preserving antigens and process for utilizing cytological material produced by same |
| US5811099A (en) | 1991-05-08 | 1998-09-22 | Streck Laboratories, Inc. | Method and composition for preserving antigens and process for utilizing cytological material produced by same |
| US5849517A (en) | 1991-05-08 | 1998-12-15 | Streck Laboratories, Inc. | Method and composition for preserving antigens and nucleic acids and process for utilizing cytological material produced by same |
| US5614391A (en) | 1991-07-19 | 1997-03-25 | Pharmacia P.L. Biochemicals, Inc. | m-RNA purification |
| US5257633A (en) | 1992-06-23 | 1993-11-02 | Becton, Dickinson And Company | Surface modified blood collection tubes |
| US5985572A (en) | 1993-02-01 | 1999-11-16 | Qiagen N.V. | Quaternary amine surfactant and methods of using same in isolation of RNA |
| US7288380B1 (en) | 1996-03-15 | 2007-10-30 | The Pennsylvania State University | Detection of extracellular translocated tumor-associated nucleic acid in blood plasma or serum using nucleic acid amplification assays |
| US7208275B2 (en) | 1996-03-15 | 2007-04-24 | The Penn State Research Foundation | Detection of extracellular tumor-associated nucleic acid in blood plasma or serum using nucleic acid amplification assays |
| US7569350B2 (en) | 1996-03-15 | 2009-08-04 | The Penn State University | Methods for selecting cancer vaccine therapies using extracellular DNA |
| US6939675B2 (en) | 1996-03-15 | 2005-09-06 | The Penn State Research Foundation | Detection of extracellular tumor-associated nucleic acid in blood plasma or serum using nucleic acid amplification assays |
| US6939671B2 (en) | 1996-03-26 | 2005-09-06 | Oncomedx, Inc. | Method enabling use of extracellular RNA extracted from plasma or serum to detect, monitor or evaluate cancer |
| US6759217B2 (en) | 1996-03-26 | 2004-07-06 | Oncomedx, Inc. | Method enabling use of extracellular RNA extracted from plasma or serum to detect, monitor or evaluate cancer |
| US20080057502A1 (en) | 1996-03-26 | 2008-03-06 | Oncomedx, Inc. | Method Enabling the Use of Extracellular Ribonucleic Acid (RNA) Extracted from Plasma or Serum to Detect, Monitor or Evaluate Cancer or Premalignant Conditions |
| US6916634B2 (en) | 1996-03-26 | 2005-07-12 | Oncomedx, Inc. | Method enabling use of extracellular RNA extracted from plasma or serum to detect, monitor or evaluate cancer |
| US6630301B1 (en) | 1997-03-14 | 2003-10-07 | The Penn State Research Foundation | Detection of extracellular tumor-associated nucleic acid in blood plasma or serum |
| US20080261292A1 (en) | 1998-09-22 | 2008-10-23 | Oncomedx, Inc. | Method Enabling the Use of Extracellular Ribonucleic Acid (RNA) Extracted from Plasma or Serum to Detect, Monitor or Evaluate Cancer or Premalignant Conditions |
| US6077235A (en) | 1999-02-23 | 2000-06-20 | Becton, Dickinson And Company | Blood collection assembly and method therefor |
| US6337189B1 (en) | 2000-02-08 | 2002-01-08 | Streck Laboratories, Inc. | Fixative system, method and composition for biological testing |
| US6551267B1 (en) | 2000-10-18 | 2003-04-22 | Becton, Dickinson And Company | Medical article having blood-contacting surface |
| US6821789B2 (en) | 2000-11-08 | 2004-11-23 | Becton, Dickinson And Company | Method and device for collecting and stabilizing a biological sample |
| US6617170B2 (en) | 2000-11-08 | 2003-09-09 | Becton, Dickinson And Company | Method and device for collecting and stabilizing a biological sample |
| US20080096217A1 (en) | 2001-07-25 | 2008-04-24 | Oncomedx Inc. | Methods for evaluating pathologic conditions using extracellular RNA |
| US20040137417A1 (en) | 2002-10-16 | 2004-07-15 | Streck Laboratories Inc. | Method and device for collecting and preserving cells for analysis |
| US7390663B2 (en) | 2005-02-23 | 2008-06-24 | Streck, Inc. | Process, composition and kit for providing a stable whole blood calibrator/control |
| US7419832B2 (en) | 2005-03-10 | 2008-09-02 | Streck, Inc. | Blood collection tube with surfactant |
| US20090081678A1 (en) | 2007-09-21 | 2009-03-26 | Streck, Inc. | Nucleic acid isolation in preserved whole blood |
| WO2010004474A2 (en) | 2008-07-10 | 2010-01-14 | Rocketic Technologies Ltd | Efficient parallel computation of dependency problems |
| WO2010096323A1 (en) | 2009-02-18 | 2010-08-26 | Streck, Inc. | Preservation of cell-free nucleic acids |
| EP2398912A1 (en) | 2009-02-18 | 2011-12-28 | Streck Inc. | Preservation of cell-free nucleic acids |
Also Published As
| Publication number | Publication date |
|---|---|
| EP3778919A1 (en) | 2021-02-17 |
| US20200318161A1 (en) | 2020-10-08 |
| US10144955B2 (en) | 2018-12-04 |
| EP2398912B1 (en) | 2017-09-13 |
| US10689686B2 (en) | 2020-06-23 |
| US20180163256A1 (en) | 2018-06-14 |
| US20230374568A1 (en) | 2023-11-23 |
| US8586306B2 (en) | 2013-11-19 |
| WO2010096323A1 (en) | 2010-08-26 |
| DK3290530T3 (da) | 2020-12-07 |
| EP2398912A1 (en) | 2011-12-28 |
| EP3290530B1 (en) | 2020-09-02 |
| US20100209930A1 (en) | 2010-08-19 |
| US10294513B2 (en) | 2019-05-21 |
| US8304187B2 (en) | 2012-11-06 |
| US20190233879A1 (en) | 2019-08-01 |
| US20180216165A1 (en) | 2018-08-02 |
| US20240218425A1 (en) | 2024-07-04 |
| US11761025B2 (en) | 2023-09-19 |
| US9657227B2 (en) | 2017-05-23 |
| US9926590B2 (en) | 2018-03-27 |
| EP3290530A1 (en) | 2018-03-07 |
| US20170260569A1 (en) | 2017-09-14 |
| NO2398912T3 (https=) | 2018-02-10 |
| DK2398912T3 (en) | 2017-10-30 |
| US20140054508A1 (en) | 2014-02-27 |
| ES2649572T3 (es) | 2018-01-12 |
| US20130034860A1 (en) | 2013-02-07 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DE202010018569U1 (de) | Konservierung zellfreier Nukleinsäuren | |
| DE202010018545U1 (de) | Blutsammelröhrchen | |
| CA2780536C (en) | Stabilization of rna in and extracting from intact cells within a blood sample | |
| WO2008145710A1 (de) | Verfahren zur stabilisierung einer biologischen probe | |
| WO2006100063A2 (de) | Reagenz und verfahren zur verhinderung der zeitabhängigen rna-expression in biologischen zellen | |
| DE202010018561U1 (de) | Blutsammelröhrchen | |
| WO2022036174A1 (en) | Sample collection containers, processes and collected samples | |
| DE102005031910B4 (de) | Verfahren zum Stabilisieren von Nukleinsäuren | |
| CA2690651C (en) | Preservation of fetal nucleic acids in maternal plasma | |
| EP2576820A1 (de) | Stabilisierung von nukleinsäuren in zellmaterial-haltigen biologischen proben | |
| WO2008145708A2 (de) | Aromatische alkohole zur behandlung einer biologischen probe |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| R207 | Utility model specification | ||
| R151 | Utility model maintained after payment of second maintenance fee after six years | ||
| R079 | Amendment of ipc main class |
Free format text: PREVIOUS MAIN CLASS: C12Q0001680000 Ipc: C12Q0001000000 |
|
| R152 | Utility model maintained after payment of third maintenance fee after eight years | ||
| R071 | Expiry of right |